HIV Primary Care
HIV Primary Care
HIV Primary Care
An essential guide to HIV for GPs, practice nurses and other members of the primary healthcare team
*The Medical Foundation for AIDS & Sexual Health (MedFASH) is a charity supported by the British Medical Association. Registered charity no: 296689.
Published by Medical Foundation for AIDS and Sexual Health BMA House Tavistock Square London WC1H 9JP Medical Foundation for AIDS and Sexual Health 2004 Acknowledgements
MedFASH is grateful for advice and comments from a wide range of individuals during the development of this booklet, including: Dr John Chisholm, Dr Andrew Dearden, Dr Stewart Drage, Dr Mustafa Kapasi and the British Medical Association (BMA)s General Practitioners Committee; the Royal College of General Practitioners (RCGP) Sex, Drugs and HIV Task Group; Dr Patrick French, Professor Brian Gazzard, Dr George Kinghorn, Dr Martin Fisher, Professor Catherine Peckham, Dr Jean Tobin (for the BMAs Dermatology and Venereology Specialty Sub-Committee), and Ruth Webb. Thanks are also due to the following for help with drafting and information: Simon Crompton, Teresa Battison, Dr Deenan Pillay, Dr Pat Tookey, BMA Ethics Department, Stonewall. The printing and dissemination of this booklet in England has been funded by the Department of Health. Development and design were made possible by the generous financial support of the BMA and by unrestricted grants from Abbott Laboratories, BristolMyers Squibb Pharmaceuticals Ltd, Boehringer Ingelheim Ltd, Gilead Sciences Ltd, GlaxoSmithKline, Merck Sharpe & Dohme Ltd, and Roche Products Ltd. MedFASH wishes to thank the West Midlands Deanery Postgraduate General Practice Education Unit for enabling Dr Philippa Matthews to contribute part of her time as an author. Illustrations and figures are reproduced with the kind permission of Dr Adrian Mindel and Dr Melinda Tenant-Flowers (from ABC of AIDS), Dr MF Spittle (from ABC of AIDS), the Health Protection Agency, Medical Illustration UK Ltd, the Science Photo Library, the Wellcome Photo Library, the RCGP Sex, Drugs and HIV Task Group and the Primary Care Facilitation Team (Blood Borne Viruses) NHS Lothian. Project management and editing: Ruth Lowbury, MedFASH executive director. Project administration: Iain Webster, MedFASH administrator. Editorial support and printing: BMA Publications Unit. Design and layout: Hilary Tranter. The authors are credited in alphabetical order. The authors would like to thank Ruth Lowbury for the enormous amount of work she has put in to this booklet. It has benefited greatly from her thoroughness and eye for detail.
Cover
CNRI/Science Photo Library False colour transmission electron micrograph of human immunodeficiency virus particles inside a stricken T4 lymphocyte, a white blood cell of the immune system. 2
HIV IN PRIMARY CARE
CONTENTS
INTRODUCTION About this booklet About the Medical Foundation for AIDS & Sexual Health (MedFASH) About the authors Foreword by Dr John Chisholm SECTION 1 CORE INFORMATION HIV in the UK: the figures Monitoring HIV in the UK The virus and the natural history of HIV infection Tests and clinical markers of HIV infection Antiretroviral therapy (ART) HIV prevention in the UK SECTION 2 HOW TO DIAGNOSE HIV IN PRIMARY CARE Opportunities to diagnose HIV in primary care Talking to patients about HIV The clinical diagnosis of HIV Primary HIV infection (HIV seroconversion illness) Clinical conditions associated with longstanding HIV infection HIV testing in primary care SECTION 3 CLINICAL CARE FOR THE PATIENT WITH HIV Looking after specific groups of people with HIV Health promotion, screening and immunisation for patients with HIV Reproductive health and fertility Managing HIV-related problems Caring for people on antiretroviral therapy (ART) Additional treatments for those with immunosuppression The patient who will not attend for specialist care The dying patient
HIV IN PRIMARY CARE
5 5 6 7 9 10 13 13 15 18 19 21 22 23 23 24 27 40 49 50 51 53 54 56 62 62 63
3
CONTENTS
SECTION 4 HIV AND THE PRACTICE TEAM Sexual health promotion and HIV prevention in the practice Working with those with diverse needs Practice policies and systems SECTION 5 QUICK REFERENCE HIV testing aide-memoire HIV testing pro forma Antiretrovirals by group Drug interactions further information A guide to managing HIV-related problems Useful sources for clinicians Useful sources for patients Bibliography SECTION 6 SUBJECT INDEX 65 66 66 67 71 72 73 74 74 75 79 81 83 84
INDEX OF PHOTOGRAPHS 1. 2. 3. 4. 5. 6. 7. 8. 9. Herpes Zoster Lipodystrophy Opportunities to diagnose HIV in primary care Primary HIV infection Kaposis sarcoma Seborrhoeic dermatitis Kaposis sarcoma Oral candida Oral hairy leukoplakia 14 18 22 24 31 32 33 34 34 35 61
INTRODUCTION
About this booklet The number of people with HIV infection continues to rise. There is no cure and no vaccine, although current treatments are life-saving. Around one third of those with HIV infection in the UK have yet to be diagnosed, even though many will be using primary care.
This booklet aims to provide essential information on HIV for GPs, practice nurses and other members of the primary healthcare team. The booklet provides: q an update on HIV and the consequences of infection q clear information on the clinical diagnosis of HIV in primary care q information on HIV testing and prevention, and strategies for introducing them into primary care q information on the management of people with HIV with a primary care focus. Comments about this booklet are welcome, and will inform future editions. Please send them to the Medical Foundation for AIDS & Sexual Health.
About the Medical Foundation for AIDS & Sexual Health (MedFASH)
MedFASH is a charity supported by the British Medical Association. It works with policy-makers and health professionals to promote excellence in the prevention and management of HIV and other sexually transmitted infections. In 2003 MedFASH published Recommended standards for NHS HIV services, endorsed by the Department of Health and the British HIV Association. These were developed for England but are relevant for all parts of the UK. Using the patient pathway as a framework, the standards address the role of both specialist and mainstream providers, highlighting the importance of managed service networks for consistent and equitable care delivery. The standards identify GPs and primary healthcare teams as playing an important part in the prevention and management of HIV, including diagnosis.
Whilst all reasonable efforts have been made to ensure the information contained in this booklet is accurate, no representations or warranties are made (whether expressed or implied) as to the reliability or completeness of such information. Neither the Medical Foundation for AIDS & Sexual Health nor the authors (either jointly or severally) can be held liable for any consequence or loss arising directly or indirectly from the use of, or any action taken in reliance on, any information appearing in this booklet.
HIV IN PRIMARY CARE
INTRODUCTION
About the authors
Dr Sara Madge works as a GP in a north London practice and is an honorary senior lecturer in the Department of Primary Care at the Royal Free and University College Medical School, London. She is also an associate specialist at the Royal Free Centre for HIV Medicine having worked in HIV/AIDS for the past 12 years. Dr Philippa Matthews is a general practitioner and GP trainer at Lee Bank Group Practice in Birmingham city centre. She also works in the West Midlands Deanery GP Unit as programme director for education in sexual health and HIV, commissioning and delivering education for primary care. She is an honorary senior lecturer at the University of Warwick. She has had an interest in HIV, sexual health and sexual history taking in primary care for many years. Dr Surinder Singh is currently a general practitioner and clinical lecturer in general practice at the Royal Free and University College Medical School, London. He has worked in sexual health and HIV since 1987. He has been chairman of the Royal College of General Practitioners HIV working party and of the Lewisham PCT working group on sexual health and HIV. He is now a member of the Independent Advisory Group on Sexual Health. He works in a small but evolving practice in Deptford and New Cross, London. He is also an associate medical anthropologist at Brunel University, Middlesex. Dr Nick Theobald trained in general practice in Bath and Wiltshire and was a GP principal in Swindon for nine years. He is currently associate specialist in HIV/genitourinary medicine at Chelsea and Westminster Hospital and Imperial College, London with responsibility for undergraduate and postgraduate education.
INTRODUCTION
Foreword
This booklet is an important addition to practice libraries. Its contents are relevant to the work of all general practitioners, practice nurses and primary care teams.
HIV continues to be one of the most important communicable diseases in the United Kingdom. It causes serious morbidity, significant mortality and the loss of high numbers of potential years of life, despite considerable advances in life-prolonging treatment that have led to a substantial reduction in the number of HIV-related deaths in the UK. Gratifyingly, HIV infection is now highly treatable. It is increasingly managed as a chronic disease, and many more patients survive for long periods. However, the costs of treatment and care remain high. Currently, nearly fifty thousand people are infected with the human immunodeficiency virus in the UK. The numbers of those infected continue to rise fast, with a 20 per cent increase in new diagnoses between 2001 and 2002. Each year, many thousands of individuals are newly diagnosed as infected. Yet estimates suggest that almost a third of patients with HIV remain undiagnosed many of whom will be using primary care. HIV-related morbidity and mortality are greater in those who are diagnosed late. Whilst much of the treatment of HIV infection is specialised, general practice and primary care have important roles in helping infected patients. Increasingly, care will be delivered through partnership between specialised centres and primary care. This booklet gives considerable help and much useful and essential advice, as well as listing further sources of information. It deals with prevention, the clinical diagnosis of HIV infection in primary care, testing, and the management of infected people in primary care, including monitoring their adherence to treatment rgimes. GPs and primary care teams can play important roles in the prevention, diagnosis and management of HIV infection, and in the care of the dying patient. Their potential involvement goes far beyond referral to specialist services. This booklet will help general practitioners promote safer sexual practices, and assist them in giving advice to drug users, particularly if their practice has been commissioned to deliver an enhanced service for those patients. GPs are involved in screening pregnant women for HIV infection. GPs and practice nurses also need to be fully aware of what
7
Dr John Chisholm CBE Chairman, General Practitioners Committee, British Medical Association 1997-2004
INTRODUCTION
action to take when a needlestick injury has occurred, including seeking rapid expert advice about post-exposure prophylaxis. General practice also provides opportunities to diagnose HIV infection, through clinical diagnosis when a patient presents with symptoms and signs that may suggest infection, and through offering diagnostic tests to those who are or may be at risk. This booklet is particularly helpful in suggesting ways of improving HIV detection, reminding GPs to be vigilant about the consequences of HIV infection including opportunistic infections and malignancies and in relation to those relatively common conditions that may signify underlying infection, and should prompt further enquiry, examination and assessment. (Throughout the text, urgent conditions and highly important information are clearly marked.) It is important to remember that people who are unaware they are infected are attending primary care. Early diagnosis can be lifesaving. This booklet also explains when an HIV antibody test should be offered and gives helpful and detailed guidance about how to raise the subject, discussing risk, the other issues that might be covered in a pre-test discussion, and how to give the result. Confidentiality, communication, continuity, sensitivity and a nonjudgmental, non-discriminatory attitude are crucial components of the care of those who are or may be infected with HIV. The authors of this booklet give helpful advice, based on their own clinical practice, on the steps that can be taken to improve that care and to reinforce the trust between doctor and patient. This booklet was initiated by the Medical Foundation for AIDS and Sexual Health whilst I was Chairman of the BMAs General Practitioners Committee. The GPC and the BMA continue to be strong supporters of the Foundations work. I am pleased to have this opportunity to commend this excellent booklet to all GPs and primary care teams, and am confident it will prove both instructive and practical.
SECTION 1
HIV core information
IN THIS SECTION
HIV in the UK: the figures Monitoring HIV in the UK The virus and the natural history of HIV infection Tests and clinical markers of HIV infection Antiretroviral therapy (ART) HIV prevention in the UK 10 13 13 15 18 18
SECTION 1
5,000
4,000
3,000
2,000
1,000
0 1993
1
1994
1995
1996
2000
20011
20021
Numbers will rise, for recent years, as further reports are received.
10
Figure 2: Number of new HIV diagnoses by year of diagnosis and probable route of exposure
3,500 3,000 2,500 2,000 1,500 1,000 500 0
19 85 19 86 19 87 19 88 19 89 19 90 19 91 19 92 19 93 19 94 19 95 19 96 19 97 19 98 19 99 20 00 20 01 20 02
KEY Sex between men Sex between men and women Injecting drug use Blood/tissue Mother to infant Other/undetermined
Year of diagnosis
Source: Health Protection Agency
Year of diagnosis
11
SECTION 1
Figure 4: Estimated prevalence of HIV infection in adults aged 15-59 in the UK at the end of 2002
Total Blood and blood products Sex between men and women (females) Sex between men and women (males) Injecting drug use Sex between men 0 5 10 15
31%
Exposure category
25
30
35
40
45
50
Undiagnosed HIV It is estimated that at the end of 2002 over 15,000 HIV-infected people remained undiagnosed almost a third of the total infected (see figure 4). HIV-related morbidity and mortality are increasingly concentrated among those who are diagnosed late. Although many of these patients will do very well, treatment is more complex and it will take longer for satisfactory CD4 counts to be reached.
12
Looking at trends in other infections Transmission risks of hepatitis B and C and sexually transmitted infections (STIs) are closely linked with the risk of HIV transmission. Therefore, increases in these rates (especially within certain groups such as injecting drug users) might herald an increase in HIV transmission.
13
SECTION 1
The consequences of HIV infection If untreated, infection with HIV results in three groups of conditions:
Opportunistic infections (OIs) Fungi, viruses, bacteria and other organisms that are usually harmless can all cause OIs. Some, such as herpes zoster, are simply commoner in the immunocompromised. Others, such as pneumocystis pneumonia (PCP, previously known as pneumocystis carinii pneumonia and, recently renamed pneumocystis jiroveci) only cause infection in the immunocompromised. People with HIV are more likely to develop symptoms and/or systemic infection with TB than those without HIV. Malignancies Some malignancies, such as lymphoma, Kaposis sarcoma and carcinoma of the cervix, are commoner in HIV infected people.
For more on the clinical problems caused by HIV infection see p27
Direct effects HIV itself causes a flu-like illness in the weeks after infection (see pages 24-26). In advanced disease it can also cause wasting, diarrhoea and neurological problems.
The Acquired Immune Deficiency Syndrome (AIDS) AIDS was a term coined before the human immunodeficiency virus was identified in order to help classify and monitor this new medical condition. A patient was said to have AIDS when they developed certain conditions, such as specific opportunistic infections. There are now much better measures of disease advancement (see pages 15-17). The term AIDS now has limited value with respect to prognosis because of great improvements in treatment. It is still used as a category in epidemiological surveillance.
14
<100
15
SECTION 1
is usually above 500 cells/L. It is normal for CD4 counts to be quite variable for example, if someone has a cold or recently had an immunisation. Therefore trends are more important than single readings. A patient with a CD4 count below 100 cells/L is likely to have had immunodeficiency problems, but it is not inevitable that they are significantly unwell. The CD4 count is an essential clinical tool in deciding whether antiretroviral therapy (ART) should be started, and when to prescribe prophylaxis against certain opportunistic infections.
Viral load This is a measure of the amount of HIV in the blood. The higher the value the more active the virus and hence the disease process. A rising viral load shows that the virus is replicating at a higher rate. The viral load should fall
Figure 5. Association between virological, immunological, and clinical events and time course of HIV infection Primary HIV Asymptomatic Symptomatic/AIDS
12 weeks
Reproduced courtesy of Adrian Mindel and Melinda Tenant-Flowers from Mindel A & Tenant-Flowers M (2001) Natural history and management of early HIV infection in Adler MW (ed) ABC of AIDS. London: BMJ Publishing Group.
16
if antiretroviral therapy (ART) is acting effectively. A rising viral load in a patient on ART can indicate a range of problems for example drug resistance may be developing, or the patient may not be taking their treatment. The viral load can range from less than 50 copies/ml of plasma (below the level of detection of most currently available assays often called an undetectable viral load) to over a million copies/ml. The aim of ART is to reduce the viral load to below 50 copies/ml. Numbers of copies per ml can go so high that results are often expressed in a log scale (eg 106 copies/ml).
How the CD4 count and viral load inter-relate If HIV is replicating out of control but the CD4 count has not yet declined, then the viral load will indicate a problem before the CD4 count. The CD4 count of people who are not on ART and who have a high viral load (for example over 104 copies/ml) will drop more quickly than that of those with a lower viral load. Once the viral load is suppressed, then the CD4 count (and the patients immunity) has a chance to recover. There is wide variation in the time it takes to progress from primary infection to symptomatic disease. Figure 5 shows the average.
17
SECTION 1
Antiretroviral therapy (ART)
For more on types of ART see p56
ART limits HIV replication. It has had an enormous impact on morbidity and mortality from HIV disease in the UK, as illustrated in figure 1. New drugs and strategies are continually being developed. The management of HIV has become more complex with the advent of antiretroviral drugs. This section gives a brief overview of the current specialist management of HIV. For aspects of management that may be encountered by the GP, see the guide to managing HIV-related problems on page 75. Antiretroviral drugs are classified into four groups, according to where and how they act in the replication cycle of the virus. They are: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) non-nucleoside reverse transcriptase inhibitors (NNRTIs) protease inhibitors (PIs) fusion inhibitors. Because HIV readily mutates as it replicates, resistance to single antiHIV drugs develops very readily. This means that currently three or more drugs are used in combinations, and that adherence to drug regimens is essential. Monitoring of ART is primarily by viral load. Clinicians are also able to access information on the resistance of the strain of HIV in an individual patient and this helps guide drug choice. After ART has started, the combination of drugs may be changed according to any side effects experienced. These will often be minor but can include more serious conditions such as hyperlipidaemia, diabetes and lipodystrophy (a syndrome characterised by redistribution of body fat).
Lipodystrophy. A syndrome probably caused by ART and characterised by redistribution of body fat. For more on lipodystrophy see p61
18
Promoting safer sexual practices Penetrative sex Condom use significantly reduces the likelihood of sexually transmitted infection (STI) and HIV transmission for both vaginal and anal sex. Condoms should be worn before penetration, and water-based lubricant should be used (oil-based lubricants degrade latex). Recent research has suggested that adequate lubrication may be more important than condom thickness in preventing condom failure. People at risk of acquiring or transmitting HIV should use condoms consistently.
For further information see Oral sex and transmission of HIV statement of risk at www.dh.gov.uk
Oral sex There is increasing evidence that oral sex, which is common in both heterosexual and homosexual relationships, can allow HIV transmission especially in the presence of oral disease (ulceration, gingivitis). For some individuals this remains the only risk factor in acquiring HIV infection. The use of (flavoured) condoms for oral sex is now recommended. Latex sheets called dental dams are available to cover womens genitalia during oral sex.
Preventing mother-to-child transmission With appropriate interventions the transmission rate of HIV from mother to baby (vertical transmission) can be reduced from about 20 per cent to under one per cent. Achieving this depends on detecting HIV before or during pregnancy. The interventions to prevent vertical transmission are: antiretroviral therapy in pregnancy antiretroviral treatment at delivery plus a short course for the baby elective caesarian section (the value of this is now being questioned in women with very low viral loads) avoidance of breastfeeding. See Department of Health All pregnant women should be offered (2003) Screening for screening for rubella antibody, syphilis, HIV and infectious diseases in hepatitis B as an integral part of their antenatal pregnancy: standards to support the UK antenatal care during their first and all subsequent screening programme. pregnancies. Antenatal testing for HIV should be recommended.
19
SECTION 1
This symbol indicates urgent conditions or highly important information
Screening blood and treating blood products All blood donations in the UK are screened for HIV. Since the introduction of screening, there have been only two proven incidents of blood infected with HIV being accepted for transfusion in the UK (still antibody negative because of the window period). All blood products in the UK are heat-treated. Preventing transmission among injecting drug users Preventing people from taking up injecting drug use through education and information strategies is one approach. For those already injecting drugs, there are: services supporting people trying to quit, and prescribing safer substitutes such as methadone or buprenorphine services supporting safer injecting practices. Needle exchanges are available in some areas. Drug users can exchange used needles and syringes for new replacements on an anonymous basis. Providing post-exposure prophylaxis (PEP): an emergency PEP is the emergency use of antiretroviral therapy (ART) to prevent transmission when a person has been at high risk of exposure to HIV. The aim is to give ART within hours of exposure. The exact choice of drug combination requires expert guidance. The medication, usually taken for four weeks, can have significant side effects, and many people are unable to continue working while taking the prophylaxis. If exposure to HIV is thought to have occurred through a needle stick injury, urgent advice should be sought. If a condom ruptures, exposing to HIV the uninfected sexual partner of someone known to be infected, many HIV treatment centres consider it appropriate to offer PEP. Some will offer it in other circumstances where there has been signficant sexual risk. This is an issue of much debate and is discussed in Department of Health guidance.
See UK Health Departments (2004) HIV postexposure prophylaxis: guidance from the UK Chief Medical Officers Expert Advisory Group on AIDS.
Immunisation Most experts agree there is little prospect for an effective vaccine in the near future.
20
SECTION 2
How to diagnose HIV in primary care
IN THIS SECTION
Opportunities to diagnose HIV in primary care Talking to patients about HIV The clinical diagnosis of HIV Primary HIV infection (HIV seroconversion illness) Clinical conditions associated with longstanding HIV infection HIV testing in primary care 22 23 23 24 27 40
SECTION 2
Opportunities to diagnose HIV in primary care. Be aware of symptoms and risks for HIV.
22
DIAGNOSING HIV
There are three important principles Be open with the patient about the clinical reasoning behind your questions A patient with a skin rash who is suddenly asked Can I ask if you are gay? will wonder what the doctor is up to and, if he is gay, whether it is wise to answer honestly. He may not engage well with the process of giving information. If, however, the doctor first lays out the clinical grounds for asking the question, the patient may be better prepared to give a full history. There are examples of how to do this later in the booklet. Be non-judgmental It is advisable to be direct but sensitive in your questioning. The more accessible and understanding you appear, the more trusting the patient will be, and the more accurate the replies. If patients perceive the clinician to be disapproving or judgmental, then they may be more likely to withhold information that is valuable for their clinical care. They may also not return for future care and follow-up. Ensure your service is (and is seen to be) confidential Some patients have great concerns about confidentiality, in primary care in particular. This may inhibit them from talking openly about For practice highly personal issues. Ensure your practice develops a policies and systems see confidentiality policy and implements it through training and p67 induction, then let your patients know that the policy is in place by displaying a confidentiality statement.
23
SECTION 2
common symptoms present. We make quick assessments to answer questions such as Could this febrile child have meningitis? or Could this headache be due to a brain tumour?. In this section we try to give the GP a realistic and pragmatic approach to improving their chances of detecting HIV infection. There are two main clinical opportunities for diagnosing symptomatic HIV infection in primary care: primary HIV infection (HIV seroconversion illness) conditions associated with longstanding HIV infection. These are dealt with in turn.
Primary HIV infection. A blotchy rash on the trunk is sometimes present 2-6 weeks after infection with HIV.
24
DIAGNOSING HIV
Symptoms and signs of primary HIV infection The patient may have none, some or all of these: fever sore throat malaise/lethargy arthralgia and myalgia lymphadenopathy. If you are thinking of glandular fever try to remember to consider HIV.
Symptoms and signs that are sometimes also present and are more specific to primary HIV infection include: a blotchy rash affecting the trunk orogenital or perianal ulceration. Other features that are less commonly present include: headache or meningism diarrhoea. Sometimes the CD4 count drops acutely at this stage of HIV infection, and so acute conditions associated with immunosuppression may also occur, such as: oral candidiasis shingles other conditions associated with immunodeficiency (see pages 27-36).
What to do if you suspect primary HIV infection Nothing is going to make this an easy consultation. Take a history and, if necessary, conduct an examination to look for further evidence of primary HIV infection. Has the person had a rash? Or sores or ulcers in the mouth or genital area? If you remain concerned, raise the subject with the patient. Illnesses like this are usually caused by viruses, for example the glandular fever or flu virus. Some quite rare viruses can also be a cause, and it is important that I dont miss them if they occur. I have no idea if you are at risk, but HIV is one of these. Discuss risks within the last 12 weeks. Could I ask you a few questions to see if you could be at risk? If you think the patient has primary useful info HIV infection, you should seek urgent advice from a specialist. Remember that an HIV antibody
test may be negative, even if HIV is the cause (see page 15.)
25
SECTION 2
case history
patient said he would consider it. The patient Mr l, a 28-year-old, had been registered with returned within a week and explained that he the practice two years, but had only attended had had unprotected sex five weeks before once before, for smoking cessation advice. with a new partner whom he met in a club. He He attended his GP saying he had flu and felt had now discussed the situation fully with his dreadful. He said he was exhausted and was partner at home, and had decided to have a now in the eighth day of his illness. He had a test. Having spoken to an on-call sore throat, ached all over and felt feverish. microbiologist, the GP took a sample which It was the severity and duration of the was to be tested for HIV antibodies and the symptoms that made the GP consider HIV p24 antigen. The latter test was positive glandular fever and HIV. First, the GP asked but the HIV antibody test was negative, the patient about rashes (he had none) and confirming primary HIV infection. Mr I was oral and genital initially distressed and ulceration. The patient The HIV p24 antigen test was overwhelmed by feelings said he had mouth ulcers. of guilt. Hospital follow-up positive, but the HIV antibody On examination the GP was arranged. test was negative, confirming could see three. Mr Is long-term primary HIV infection. After discussing partner, Mr W, was also glandular fever, the GP registered with the raised the subject of HIV, and explained that practice. The couple were seen together and very rarely an illness like this might be caused it was established that they had had one in the early weeks of HIV infection. The GP episode of unprotected sex between the time took a partner history and established that Mr Mr I had contracted the infection and the time I lived with his male partner, a relationship of he initially saw the GP. Then they didnt have six years. Mr I indicated that he felt that his sex until some time after HIV infection was relationship was mutually monogamous. confirmed. Mr W tested negative both initially There was no history of drug use. and three months later. Six months after this The discussion appeared to make the the relationship had survived and the couple patient anxious, so the GP said: On the basis were continuing to practise safer sex. Mr I of what you have told me your illness is was optimistic and had returned to work. The unlikely to be primary HIV infection. The GP couple told the GP that they felt that Mr W asked if the patient would be interested in had been saved from getting HIV because the having an HIV test in any case and the GP had been so on the ball.
26
DIAGNOSING HIV
27
SECTION 2
1. Respiratory conditions Cough, sweats, shortness of breath and weight loss may be caused by several opportunistic infections, including ordinary bacterial infections. Pneumocystis pneumonia (PCP) is the most important infection not to miss in the short term. TB is also important. Occasionally, lymphomas or Kaposis sarcoma may affect the lungs in HIV infected patients.
PCP This is a life-threatening infection with symptoms which may have an insidious onset progressing over several weeks. Arguably, PCP is the single most dangerous trap for the unwary GP as it may be the first HIV-related clinical problem the patient has. The prognosis correlates directly with how early or late the infection is identified and treated: PCP can kill if diagnosed late.
Symptoms a persistent dry cough of a few weeks duration increasing shortness of breath or decreasing exercise tolerance: I first noticed it when I ran for a bus, but now I feel short of breath just sitting difficulty in taking a full breath (this reflects loss of elasticity of the lung tissue) fever (in most but not all) Assessment The chest may be clear on auscultation especially in early stages. Fine crackles may be heard. Chest X-rays may reveal little If PCP is a possibility, and can lead to delay. The GP may be thinking of look for evidence of HIV. asthma, an atypical chest infection or anxiety. If PCP is a possibility, look for evidence of HIV: see the guidance for assessment on page 27 and also boxed information on page 36. Management/referral Refer patients urgently if you are concerned they may have PCP, which can only be diagnosed by hospital-based tests such as sputum cytology (and often bronchoscopy). An HIV antibody test may cause inappropriate delay. This condition is also important to detect in any patients known to have HIV, and who have CD4 counts of less than 200, even if they are on medication to prevent this.
28
DIAGNOSING HIV
TB and atypical mycobacterial disease TB is an important and common presenting problem in HIV-infected patients in the UK. It can occur at CD4 counts above 200. Atypical mycobacterial disease (mycobacterium avium intracellulare) is a less common complication, associated with late stage HIV infection.
Symptoms Patients may have a cough, fever, sweats, shortness of breath, weight loss or haemoptysis. They may have associated large, asymmetrical nodes. Mycobacterium avium intracellulare may present with systemic symptoms and chest symptoms may or may not be present. Abnormal liver function, or anaemia may be found. Assessment Your usual assessment for TB (eg CXR) and look for evidence of HIV: see guidance on assessment on page 27 and boxed information on page 36. Mycobacterium avium intracellulare is very unlikely in a patient without several clinical pointers to HIV disease, because it occurs at very low CD4 counts.
Management/referral Urgent outpatient or inpatient referral will be required, although an HIV test could also be arranged and may save For RCP guidelines on HIV testing, see Rogstad et al (2004) HIV testing for time if the patient is not too unwell. National guidelines on patients attending general medical HIV testing from the Royal College of Physicians (RCP) services:concise guidelines. recommend that all patients with indicator diseases Clin Med 4:136-9. (including TB) or symptoms be offered HIV testing.
Ordinary chest infections Chest infections which respond to the antibiotics usually employed in community settings are commoner in immunosuppressed patients.
Assessment Look for evidence of HIV: see guidance on assessment on page 27. Management/referral As usual for chest infections, but offer an HIV test if appropriate.
29
SECTION 2
2. Conditions causing neurological and visual symptoms A great variety of intracranial or peripheral neurological problems may occur in relation to HIV infection. Symptoms and signs include: headache, neck stiffness or photophobia focal neurological signs suggesting intracranial space occupying lesion peripheral neuropathy (especially sensory change or loss) confusion, memory loss, or disinhibition fits.
Cryptococcal meningitis This may present with headaches without the classical symptoms or signs of meningism.
Assessment Apart from a neurological assessment and general examination, look for evidence of HIV. See guidance on assessment on page 27. Management/referral The patient will need to be referred urgently. An HIV test may not be appropriate if the patient is very unwell.
Cytomegalovirus (CMV) infection of the retina CMV infection of the retina causes blindness and is treatable only if caught early. It is also important to detect in those patients known to have HIV, and who have CD4 counts of less than 100. The patient may have: For CD4 floaters counts see reduced vision p15 scotomas. Pain is not a feature.
Assessment Changes may be visible on fundoscopy, but the absence of changes should not alter management. Look for evidence of HIV: see guidance on assessment on page 27. CMV retinitis is very unlikely in a patient without several clinical pointers to HIV disease, because it occurs at very low CD4 counts. Management/referral The patient will need to be referred urgently to ophthalmology.
30
DIAGNOSING HIV
Kaposis sarcoma.
WELLCOME PHOTO LIBRARY
This tumour is associated with immunosuppression and has a variety of appearances on the skin.
3. Tumours associated with HIV Lymphoma Lymphoma may cause lymphadenopathy, fevers, night sweats and abdominal masses. It may be cerebral (see neurological problems, page 30).
Assessment Look for evidence of HIV. See guidance on assessment on page 27.
Management/referral As for any suspected cancer. It may be appropriate to arrange an HIV test.
Cervical carcinoma Cervical cancer may cause vaginal bleeding or discharge. Cytological abnormalities may also be a marker for underlying HIV infection.
Assessment and management/referral As normal for suspected cervical cancer. Offer an HIV test if appropriate.
Kaposis sarcoma (KS) These tumours may occur in a variety of places. They most commonly appear as dark purple or brown intradermal lumps that sometimes look like bruises (but feel harder). KS may also be found in the mouth. Infiltration of the lungs or gut is rare but can be very serious, the latter causing GI bleeding. KS may cause weight loss.
Assessment and management/referral Refer to HIV specialist. May require urgent medical admission if lung or gut involvement.
HIV IN PRIMARY CARE
31
SECTION 2
4. Constitutional symptoms associated with HIV Constitutional symptoms may be caused by HIV itself, or by a related opportunistic infection (such as TB) or tumour (such as a lymphoma). Symptoms include: fever weight loss sweats lymphadenopathy (HIV is particularly likely if this persists in excess of three months, in two or more extra-inguinal sites and in the absence of any other cause).
For guidance on assessment see box on p27
Assessment Look for evidence of HIV. Management/referral Urgent outpatient or inpatient assessment is sometimes appropriate. Alternatively arrange an HIV test.
32
DIAGNOSING HIV
Kaposis sarcoma. This tumour may also rarely affect the gut or lungs.
5. Skin conditions Look out for common skin conditions that are particularly severe or hard to treat. Review the records for other evidence of HIV infection. Examples include: fungal infections, such as tinea cruris, tinea pedis, pityriasis versicolor viral infections, such as shingles (especially if more than one dermatome is affected), molluscum contagiosum, warts and herpes simplex bacterial infections, such as impetigo, folliculitis Kaposis sarcoma (see description on page 31 and photographs on pages 31 and 33) other skin conditions, such as seborrhoeic dermatitis (see photo opposite) and psoriasis.
Assessment Look for evidence of HIV. See guidance on assessment on page 27, and also boxed information on page 36. Management/referral As usual, and arrange an HIV test if appropriate.
33
SECTION 2
6. Conditions affecting the mouth Immunosuppression can lead to a number of conditions affecting the mouth, and examination of the mouth is key in assessment, as some of the conditions may be asymptomatic. Examples include: oral candidiasis (thrush): not just a coated tongue, but thick white plaques on the buccal mucosa that can be scraped off with a important! tongue depressor. Swabs are of little diagnostic value because of Florid oral thrush high carriage rates. should always lead aphthous ulceration to a consideration of oral hairy leukoplakia: causing whitish corrugations, typically on whether the patient the side of the tongue. They cannot be scraped off. It is usually could be asymptomatic, but is pathognomonic of immunosupression. It is immunosuppressed useful to look for this if you suspect a patient may have HIV disease Kaposis sarcoma: purple tumour, characteristically on the palate (see page 35) gingivitis dental abscesses.
Assessment Look for evidence of HIV: see guidance on assessment on page 27, and also boxed information on page 36. Management/referral As usual and arrange an HIV test if appropriate.
34
DIAGNOSING HIV
7. Conditions affecting the upper and lower GI tract Significant conditions include: oesophageal candidiasis: the patient presents with dysphagia suggestive of an oesophageal problem, but is highly likely to have concurrent oral thrush diarrhoea persistent mild, or severe acute. There may be virtually any or commonly no causative organism found.
For guidance on assessment see box on p27
Assessment Look for evidence of HIV. Management/referral As usual and arrange an HIV test if appropriate.
8. Genital problems Sexually transmitted infections (STIs) such as genital herpes or genital warts may be more severe in the immunosuppressed patient. In addition, severe or difficult to treat genital candida may itself be a clue to immunosuppression. The diagnosis of any STI should lead to a consideration of the possibility of other STIs, including HIV.
Assessment Look for evidence of HIV: see guidance on assessment on page 27, and also boxed information on page 36. Management/referral As usual and arrange an HIV test if appropriate.
From left to right: Oral candida. This condition is an important indicator of immunosuppression. Oral hairy leukoplakia. Pathognomonic of immunosuppression. Palatal Kaposis sarcoma. This tumour gives another reason for careful examination of the mouth when looking for evidence of HIV.
DR MF SPITTLE
35
SECTION 2
9. Haematological problems Changes found on routine full blood counts may give a clue to immunosuppression. They may be severe enough to require urgent action, but are often more subtle, with few symptoms. Examples include: neutropenia anaemia thrombocytopaenia.
For guidance on assessment see box on p27
Assessment Look for evidence of HIV. See guidance on assessment on page 27 and box below. Management/referral As usual and arrange an HIV test if appropriate.
What to do if you suspect HIV infection may underlie the presenting problem
If the problem is clinically minor (seborrhoeic dermatitis in a patient who had multidermatomal shingles two months ago), it may be reasonable to arrange an early review of the patient in order to give yourself time to collect your thoughts. But dont risk losing patients to follow-up. Remember that resolution of the presenting problem does not mean that HIV has been ruled out. Enquire about weight loss, sweats, diarrhoea Examine the patient for other signs of immunosuppression (mouth, skin and nodes, see pages 32-34) Review the records for evidence of HIV-associated problems in the last three years (see list, pages 28-36) Discuss the possibility of HIV with the patient to consider their risk.
For many GPs quite understandably raising the subject with the patient is the difficult bit. Something along the lines of the following formulae might work: The problems that you have had recently are quite common, and usually minor. However, very occasionally they can give a clue that your immune system is not working as well as it should. I dont know if you are at risk of HIV, but this is one condition For more that can affect the immune system. Could I ask you some questions to details on risk see if you could be at risk? . assessment, Decide on priorities: is urgent assessment by a specialist required see p41 or can an HIV test be offered? If the clinical picture is strongly suggestive of HIV, an apparent absence of risk of infection should not deter the GP from offering the patient a test From what you tell me you are quite unlikely to have HIV. Do you think it would be wise to do a test anyway so that we can be sure?
36
DIAGNOSING HIV
case history
Late diagnosis of HIV and tuberculosis
2-3cms hepatomegaly and otherwise no focal Miss J is a 26-year-old woman who came to signs in her chest, abdomen or CNS. the UK from Sierra Leone two years ago. She She was treated with multiple antibiotics saw her GP with a six-week history of fevers, but did not improve. Following discussion with intermittent cough and cervical a member of the HIV team she reluctantly lymphadenopathy. Nine months previously she agreed to a test for HIV antibodies, which was had attended her GP with positive. She was She had been complaining of fatigue and was found to eventually diagnosed with non-specific fatigue/malaise tuberculosis following have mild anaemia. Now for at least eight or nine she was prescribed sputum culture. Penicillin V, which The history that months, for which the full alleviated her symptoms emerged when she felt blood count had been the for a few days. A week better was that she had only investigation. later she presented again been feeling ill for at least with rigors, night sweats and weight loss. She six to eight weeks, and had had intermittent was admitted to hospital for investigation of a fevers (and some night sweats) for three pyrexia of unknown origin with malaria at the months. She had been complaining of nontop of the differential diagnosis. specific fatigue/malaise for at least eight or She was found to have non-tender nine months, for which the full blood count rubbery lymphadenopathy in her axilliary, had been the only investigation. She might not inguinal, supraclavicular and cervical areas. have agreed to an HIV test at this time, but an On admission she also had a fever of 39.4C earlier diagnosis might have enabled her to and a tachycardia. She was hypotensive, had avoid hospitalisation.
case history
A newly registered African woman
Miss H is a 34-year-old Zimbabwean who had just registered with her GP. Her new patient check noted that her child had died in Zimbabwe before she came to this country three years ago. When her records came they showed she had had a previous abnormal smear (CIN 1). Miss H attended the surgery because of recurrent genital itching. She described her current health as good. On examination she was found to have genital herpes and molluscum contagiosum. The GP also found cervical lymphadenopathy. She had no other rashes and no oral conditions suggestive of HIV. On further questioning her GP ascertained she had no history of previous sexually transmitted infections and had never been tested for HIV. The GP suggested that an HIV test was done, and the patient agreed. The result was positive, information which Miss H took surprisingly well. Miss H was referred to the HIV clinic and soon after commenced on ART. Currently, she is quite well and continues to work. On several occasions since her diagnosis she has thanked her GP for suggesting the HIV test. She had felt she was not at risk and is glad that she had the test before she became seriously unwell.
37
SECTION 2
case history
A low-risk man
done so. Serology for hepatitis B was Mr R is a 33-year-old university lecturer of UK negative. Physical examination by the hospital origin who first presented to the practice nurse consultant revealed no abnormalities and an during a new patient medical following a house ultrasound of his liver was arranged. move. He lived with his girlfriend of eight years. Another three weeks passed, with no scan At registration he complained of a rash on his appointment arriving. Mr R reported a face. This was red, dry and flaky and affected his worsening of his cough and extreme fatigue. forehead and his naso-labial folds. He was given He had marked dyspnoea on exertion. Two a topical hydrocortisone/antifungal cream. days later his girlfriend took him to casualty. By Twelve months later he returned to the this time his dyspnoea had worsened, his practice and saw a locum GP following three weight loss continued and he had a dry cough. days of non-specific abdominal pain and He was found to be tachypnoeic and hypoxic. fever. He returned again to the practice after His CXR showed patchy shadowing. The 10 days with a dry cough, medical team felt he With no apparent risk factors probably had fatigue and lethargy. He to suggest a significant was given a broadpneumocystis pneumonia spectrum antibiotic but 14 probability of HIV infection, (PCP). This was later days later was worse, and and with such an insidious confirmed on had developed a bronchoscopy. Mr R tested onset, the diagnosis eluded generalised maculopositive for HIV antibodies many practitioners until Mr R and his CD4 count was papular rash. The facial was quite seriously ill. rash had returned, since only 10. Following the he had run out of cream. successful treatment of his He had lost 4kg of weight. PCP and initiation of antiretroviral therapy, he Frustrated at being off work for so long, he returned to work and remains well. requested a referral to the local hospital where With no apparent risk factors to suggest a significant probability of HIV infection, and he was seen by a consultant physician three with such an insidious onset, the diagnosis weeks later. Tests carried out by the GP in eluded many practitioners until Mr R was quite advance revealed a slight thrombocytopaenia, seriously ill. It is probable that he acquired HIV mild elevation of his liver transaminases and a through a sexual contact many years raised ESR. A chest X-ray was reported as previously when he was travelling in Thailand normal. Mr R was asked if he had ever and the Far East in his student years. injected drugs and stated that he had not
38
DIAGNOSING HIV
case history
A delayed diagnosis
hospital for two nights as he appeared to have Mr G is a 49-year-old divorced architect. He developed an aspiration pneumonia. Broadattended his GP some months ago with spectrum antibiotic treatment did very little diarrhoea and weight loss. Stool and he was re-admitted four days later. culture/microscopy revealed no apparent Bronchoscopy confirmed a diagnosis of PCP, pathogen and there was little response to antifor which he was admitted and treated without diarrhoeal medication. He further complication. He was not embarrassed to was referred to the local The only recorded hospital where he was seen tell the doctors that he had social history was that he sex with other men, but and placed on the waiting was divorced and smoked list for both upper GI nobody had ever asked him. 20 cigarettes daily. He endoscopy and a flexible was not embarrassed to sigmoidoscopy. This was performed four tell the doctors that he had sex with other months after the original referral letter, his men, but nobody had ever asked him. He was symptoms having continued and his overall not surprised by the subsequent HIV weight loss being some 10 per cent of his diagnosis. His CD4 count was 49 and he has original weight. done well since starting combination After the procedure he had to stay in antiretroviral therapy.
39
SECTION 2
HIV testing in primary care
Reducing the amount of undiagnosed HIV in the UK is a priority. Individuals who know they are infected with HIV have significant advantages over those who are infected but unaware of this. They will: benefit from the effectiveness of current treatments resulting in a radically improved prognosis have information which may enable them to reduce further transmission of the virus have the opportunity to reflect and plan ahead.
1. The practicalities What is the HIV test? It is a test for antibodies to HIV. It is important to remember that the test may not become positive until three months after the person has become infected (the window period).
useful info
Recent joint guidelines provide more detailed advice for doctors (Association of British Insurers & British Medical Association (2002) Medical information and insurance: joint guidelines from the British Medical Association and the Association of British Insurers). Insurers should only ask the applicant whether they have tested positive for HIV. See also updated guidance on confidentiality from the GMC, Confidentiality: protecting and providing information (2004) at www.gmc-uk.org. GPs should be guided by clinical need above all other considerations.
HIV testing and insurance reports GPs should not allow insurance concerns to compromise patient care: if an HIV test is appropriate, it should be offered. In the past there has been a reluctance to use HIV tests as a diagnostic tool in primary care. This may be due, in part, to concerns about the possibility that a doctor or patient may have to declare HIV testing (regardless of result) on a GP insurance report form. However, as long ago as 1994 the Association of British Insurers stated that a previous negative HIV test should not affect the application. Laboratory support The lab will need a clotted sample. Some smaller hospital laboratories only run HIV antibody tests on certain days. Phone the lab to check: when HIV tests are processed when the results will be available what their procedure will be if they find an apparent positive. Links with specialist HIV treatment centre(s) The best time to find out about local HIV treatment centres, and establish links with them, is before you have a patient who tests positive. In this way, clear referral pathways can be in place, including details of who to contact if a patient needs to be seen urgently by a specialist.
Computer and paper systems to support HIV testing See page 68 for discussion of systems and record keeping.
40
HIV IN PRIMARY CARE
DIAGNOSING HIV
2. When should an HIV antibody test be offered? There are a number of circumstances in which it is appropriate to conduct an HIV test: the patient may request an HIV test the patient may have an identified risk the patient may have symptoms or signs of HIV disease the patient may be in a group offered screening tests for HIV.
The patient who requests an HIV test Patients requesting an HIV test will have a reason you may choose to be reassuring but avoid discouraging patients from testing and take care before declining to test. Be flexible: some people with HIV may have no apparent risk. Patients may or may not be prepared to discuss their risks with you. You do not always need to know what risk there was, as long as the patient understands the significance of the three-month window period and what constitutes risk. If doubts remain, arrange a second test in three months. The patient may have an identified risk Because HIV infection can be asymptomatic for so long, the only hope of improving primary care detection rates in this group is if clinicians are willing and able to discuss risk of HIV and offer tests as appropriate. Risk of HIV can be identified through taking a drug and sexual history for the purposes of health promotion. The following people should be offered a test if they have never been tested, or if they have had further risk since their last test. Those who: have a current or former sexual partner who is infected with HIV, or from an area with a high prevalence of HIV or who was an injecting drug user have had anal or oral sex between men (though the latter is much lower risk) are from an area with a high prevalence of HIV (although risk should be discussed without pre-judgment as many people in this group may be at no risk) have had multiple sexual partners have a history of sexually transmitted infection have a history of injecting drug use have been raped (although in an acute situation this is best managed by specialist services if the patient will attend) have had blood transfusions, transplants or other risk prone procedures in countries without rigorous procedures for HIV screening in these circumstances may have had an occupational exposure. Careful condom use may well have offered significant protection this should be acknowledged, even if testing still goes ahead. Be ready to test
HIV IN PRIMARY CARE
41
SECTION 2
Raising the subject of an HIV test
Communication strategies Raise the subject of HIV before a sexual history has been taken perhaps in a contraception or smear consultation. HIV is much more common in people from Africa. Do you know people who have been affected? As it is a serious, but treatable condition, could we discuss whether you might have been at risk? Raise the subject of sexual health in a new patient check. We find that quite a lot of young men are at risk of having sexual health problems. Could I ask you a few questions to see if you are at risk? Raise the subject of HIV once a sexual history has been taken. Because two of your partners in the last year have been male, like you, it is possible that you are at higher risk of HIV. Have you ever considered having an HIV test? Raise the subject of HIV when a history of injecting drug use has been identified. Current advice is that everyone who has injected drugs in the past should be offered a test for HIV, because this condition responds so well to treatment. Have you ever considered having a test? Remember to emphasise the benefits of earlier HIV diagnosis.
anyone who requests an HIV test after their history has been taken, even if they have not indicated a specific risk to you. The patient may have symptoms or signs suggestive of HIV disease See pages 23-36 for clinical diagnosis and pages 23 and 36 for communication strategies in this context. The patient may be in a group offered screening tests for HIV Screening will sometimes be offered in a specialist setting, and sometimes in primary care. For example: women in antenatal care, in order to prevent mother to child transmission those found to have conditions important! which may be associated with HIV (such as TB, lymphoma, Make sure all pregnant hepatitis B or C, syphilis or other women are offered and STIs). recommended an HIV test. It is important that the value of the HIV Interventions can reduce the test is explained to the patient. risk of mother to child
transmission from 20% to 1%.
42
DIAGNOSING HIV
3. The pre-test discussion Given here is a breakdown of the items that might be covered in a pre-test discussion. Not all areas will need to be covered with all patients. The time a discussion takes is extremely variable. In a well-informed, reasonably low risk person it may take just a few minutes. A checklist is given on page 72 which can be used as an aide-memoire by the GP or practice nurse conducting an HIV test.
i) Check the patients understanding of HIV Assess their understanding of different transmission routes. They need to be aware of the difference between HIV and AIDS and should be clear about the medical advantage of knowing their HIV status. Some patients believe that if they have had any blood tests in the past, they will automatically have been tested for HIV. The patient should understand the significance of the three-month window period and that a repeat test may be needed. ii) Discuss risk to date Knowing the nature of the risk enables the clinician to tailor advice on risk reduction, and knowing the timing of risk(s) is important because of the window period (see page 15). If doubt about the window period remains, simply arrange a second test in three months. If the patient does not wish to discuss their risk, but wishes to go ahead with a test, they should be able to do so as long as the benefits of discussing risk have been mentioned. See page 41 for risks that may be discussed. If the patient is unwilling to go into detail, it may be best simply to address the issues on the HIV aide-memoire (page 72) in order to maintain the doctor-patient relationship. iii) Discuss future risk and risk reduction This may be the first opportunity that a patient has had to discuss how to keep themselves safe. It may be best to discuss safer sexual practices and safer injecting practices before the test, rather than just when the result is given, not least because risks may be taken before the patient is next seen. If a repeat test is to be arranged, emphasise that HIV transmitted by any risks between now and the next test will not show up in that result. iv) Discuss the implications of a positive test How is the patient likely to react if the result is positive? What would their main concerns be if they tested positive? What will be the reactions of those they might tell? What might be the implications for their partner? For their work?
43
SECTION 2
v) Explain confidentiality Explain that a positive test result will need to be recorded in their medical records so that their healthcare remains safe and appropriate. It will also have to be disclosed to insurance companies if requested (negative tests do not have to be disclosed). vi) Discuss how they will cope with the wait Ask the patient to consider who knows they are having a test, and who it is safe to tell. Ask the patient not to drink alcohol or take drugs on the day of the result. Consider whether there is any written information that should be given to the patient. vii) Consider if the test is best conducted in primary care In people with multiple problems (those with psychological or emotional problems, those with additional counselling needs, or those who may react badly to a positive result) a referral to GUM services for testing may be appropriate. However, this should be balanced against the benefits of having a test conducted in more familiar surroundings and by a clinician known to the patient. viii) Consider whether other tests are appropriate It may be appropriate to request other tests at the same time as HIV. For example: if the risk is considered to be due to needle sharing, talk to the patient about testing for hepatitis B and C if the risk is unprotected sexual intercourse particularly if the risk appears high then you may wish to discuss tests for other STIs such as chlamydia, syphilis or hepatitis B. There is a growing trend for specialist clinics to offer routinely tests for hepatitis B and C, and syphilis, alongside HIV. If your patient proves to be infected with HIV they may arrange these tests. Consider the need for immunisation against hepatitis B. xi) Consider whether repeat tests are required Ensure the patient understands fully if they are going to need a repeat test (to cover the window period) before current HIV infection can be ruled out. Emphasise that HIV acquired by any risks between now and the next test will not show up in the next result. x) Check whether the patient has given clear consent to HIV (or other) tests Informed consent must be obtained before any test. You can ask: Shall we go ahead with the HIV test?
44
HIV IN PRIMARY CARE
DIAGNOSING HIV
xi) Check whether you have their contact details Record contact details, and check their preferred method of contact and any possible problems with leaving messages or talking. You will be glad of this if the patient fails to attend for a result that turned out to be positive. xii) Arrange an appointment for the result to be given Try to ensure that you are not going to give a result at a bad time for example, a Friday evening surgery. A good rule is to arrange to give the result face to face. If you arrange to give the result by phone, and then later ask the patient to come to the surgery instead, this can cause severe anxiety. If, however, you have arranged to meet face to face but the result is negative, you can always ring them. xiii) Check if the patient has a supply of appropriate condoms and lubricant
4. Giving the result If the result is negative, you will need to consider whether the patient needs a further test because of the window period. When giving a negative result, dont forget to reinforce advice about minimising risk, if appropriate. If the result is positive, there are many things you need to consider before the patient attends.
Preparing to give a positive result You will have time to collect your thoughts and seek advice, because the lab is likely to phone the result through and ask for a repeat sample. Remember: you already have skills in discussing very difficult things the patient chose you to do their test, so they chose you to give them the result. Review the consultation when you took the test: what were the patients main concerns should the test be positive? who knew they were being tested? where do they get support? is there a partner whose needs you should discuss with the patient? (Formal partner notification should be addressed by the HIV clinic.)
See the newly diagnosed person on p50
Consider referral arrangements: the patient will need to be referred to a specialist HIV clinic, so an appointment can be made in advance. have available some relevant literature and phone numbers of support organisations. see also The newly diagnosed person page 50.
45
SECTION 2
When the patient attends Give the result soon after the patient is in the room and has sat down. Delaying disclosure can heighten anxiety. This also gives you more time to attend to and deal with the patients reactions. Some patients are expecting a positive result and may be quite calm. Indeed, some may have already come to terms with being positive. But remember a calm exterior can also mask a sense of shock. In the case of a positive result, listen You should emphasise the carefully and make the discussion as focused positive aspects; patients and tailored to the individual as possible. are better off knowing that Touch on the issues raised when the test was taken. For example: You said last week that if they have HIV. the result was positive your main concern would be Perhaps we should think about that now. You should emphasise the positive aspects; patients are better off knowing that they have HIV. When the consultation is coming to an end: give the patient the details of any appointment that you have arranged remember that risk reduction advice to protect partners will need to be addressed, but this may be hard for the patient to take in at this consultation consider when you are planning to see them next.
46
DIAGNOSING HIV
case history
An opportunity to test for HIV
monogamous, but he had had several partners Mr P, aged 26, attended the practice nurse for prior to this. She asked about condom use and a new patient check. He was an accountant, established that he had had significant risk of and generally fit and well with no significant exposure to HIV through several casual past medical history. The practice encouraged sexual contacts in years gone by. Mr P sexual health promotion, and the nurse raised explained that he had always meant to have a the subject once other test for HIV, but never got The couple were very aspects of the check were round to it. He had also grateful to the nurse for complete. discussed it with his having dealt with an issue She asked him if it was partner in the past, but okay if she asked questions that had been a suppressed more recently the subject to see if he could be at risk had been forgotten. but niggling worry. of any sexual health After discussion it was problems. He agreed, but seemed to become agreed that Mr P would suggest to his partner a bit guarded. The nurse took a partner history that he also registered as it seems a really according to her routine, avoiding nice practice. The nurse agreed she would be assumptions. The patient opened up and happy to arrange an HIV test for both of them. relaxed, and shortly explained that he wasnt In due course, both attended. The HIV tests living alone as he had told her, but was gay were negative. The couple were very grateful and living with his partner of three years. He to the nurse for having dealt with an issue that felt this relationship was mutually had been a suppressed but niggling worry.
47
48
SECTION 3
Clinical care for the patient with HIV
IN THIS SECTION
Looking after specific groups of people with HIV Health promotion, screening and immunisation for patients with HIV Reproductive health and fertility Managing HIV-related problems Caring for people on antiretroviral therapy (ART) Additional treatments for those with immunosuppression The patient who will not attend for specialist care The dying patient 50 51 53 54 56 62 62 63
SECTION 3
50
CLINICAL CARE
immunity may need to consider this and contact a solicitor to write a will (see The dying patient, page 63).
4. African people There may be organisations offering support to people with HIV of African origin in your area your patient may (or may not) wish to be put in touch with them. Some of these patients are asylum seekers or refugees who may have lost family members to violence and have fled their country. HIV may, for some, be the least of their immediate problems. Some asylum seekers may ultimately be returned to countries where HIV treatment is unavailable to them. Diagnosis in an adult may immediately lead to concerns about their children, who may well have been born in a country not intervening to prevent vertical transmission. There may be language difficulties, and consultations with an interpreter may need to be arranged. Finding interpreters may lead to serious concerns about confidentiality for patients living within their community. 5. Injecting drug users There may be organisations in your area that offer specialist counselling or support to drug users. Some organisations offer specific support for those who are infected with HIV. Do not assume that all injecting drug users are fully aware of the risks of sharing equipment or using non-sterile needles. It does no harm to repeat and reinforce the message. Low self-esteem, being in prison, previous abuse and other psychoemotional problems may be underlying issues that affect this group.
51
SECTION 3
important!
All women with HIV infection should have annual smears with more frequent follow-up and colposcopy if abnormalities are found.
2. Cervical screening Women with HIV (especially if they have a low CD4 count) are more at risk from human papilloma virus-related disease, including cervical cancer and warts. All women with HIV infection should have annual smears with more frequent follow-up and colposcopy if abnormalities are found. 3. Immunisation The practice can and should play a key role in immunising patients who have HIV. Current advice should always be based on the most recent edition of The Green Book (Department of Health (1996) Immunisation Against Infectious Disease), unless practitioners are informed otherwise. In general, live vaccines should be avoided. Individuals with HIV infection should not normally receive BCG, yellow Check for updates fever, or oral typhoid. Live oral polio (Sabin) immunisation and replacement chapters to The has now been withdrawn. All inactivated immunisations Green Book: such as pertussis, diphtheria, tetanus, inactivated polio www.dh.gov.uk, (Salk), typhoid, and meningitis C are safe. go to
Adults with HIV should be offered: influenza immunisation each year hepatitis B testing and immunisation as appropriate hepatitis A immunisation for men who have sex with men. In addition, they may be offered: pneumococcal immunisation.
immunisation against infectious disease
Specialist advice should be sought from the paediatric team about immunisation of children infected with HIV, and children of parents with HIV. If a baby is born to a mother with HIV, transmitted infection will usually have been identified by eight weeks. Inactivated polio is now given to all babies as standard. This is safe whether or not a baby is infected with HIV and whether or not family members are immunocompromised.
4. Advice and immunisation for international travel Hepatitis A and B vaccination should be offered as appropriate. Malaria prophylaxis is used, but interactions can occur. The antiretroviral, ritonavir, for example, can interact with several antimalarials. Check on useful info www.hiv-druginteractions.org If a yellow fever certificate is required, then a letter of exemption from a medical practitioner will normally allow Some countries restrict entry entry. The reason for the exemption need not be specified. for those with HIV. Patients For patients with HIV travelling to areas where medical should check with the relevant support may be difficult to obtain, GPs might supply a embassy or embassies before couple of courses of ciprofloxacin for travellers diarrhoea, planning their trip. together with advice on hygiene and food preparation.
52
HIV IN PRIMARY CARE
CLINICAL CARE
Advice on safer sex and the avoidance of sexually transmitted infections may need to be reinforced. Patients may also be offered a concise medical summary, including prescribed medication, in case of illness abroad.
5. Cardiovascular disease prevention It is possible that people with HIV are at higher risk from cardiovascular disease. In addition, dyslipidaemias and diabetes are associated with antiHIV therapy (see ART side effects page 58), although their impact on the cardiovascular system is unclear. Effort should therefore be put into promoting healthy diets, exercise, alcohol control, blood See sideeffects of pressure checks and smoking cessation. Bupropion should ART p58-62 only be prescribed after obtaining expert advice if people are taking PIs or NNRTIs, because of potential interactions.
53
SECTION 3
exposure to HIV (and thus the risk). Sub-fertility should be addressed in the usual way, although HIV status should be made clear if the couple is referred.
3. Antenatal and postnatal care Some patients with HIV may be well and actively choose pregnancy. Some may have an unplanned pregnancy that they choose to continue. Some may have undergone the traumatic experience of discovering through antenatal HIV testing that they are infected with HIV. Managing the pregnancy of a woman with HIV is strongly influenced by the need to prevent transmission to the baby. The risk of transmission can be reduced from around 20 per cent to under 1 per cent by the interventions given on page 19.
Support of bottle feeding There is evidence that breastfeeding doubles the risk of HIV transmission, and mothers with HIV are advised to bottle feed. This message may not be accepted by all for some groups breastfeeding has deep symbolic meaning. Unfortunately, the choices in such circumstances are stark, and advice and support should be available from midwives and others involved in care. GPs are able to prescribe formula feed if they feel it is appropriate. Asylum seekers Asylum seekers identified as HIV positive (commonly through antenatal screening) face particular financial difficulties. Amended asylum support regulations allow a payment to be made to women and children who are being supported by the National Asylum Support Service (NASS) to help towards the cost of infant formula for children up to three. Pregnant women who are being supported by the NASS can receive 3 a week assistance towards the cost of milk for the duration of their pregnancy.
CLINICAL CARE
It is important for GPs to have active communication with specialist HIV clinics. They should expect to be written to regularly, and should be prepared to notify specialists in return if there are significant changes in the patients management or circumstances.
Health problems Physical problems caused by HIV infection are significantly less common in the diagnosed patient now that ART is widely used. A patient with HIV who presents with symptoms might have: problems which relate to HIV disease (check the most recent CD4 count) side effects of ART an unconnected problem. You may be able to take the first steps to distinguish which of these is the case. A recent CD4 count that is comfortably above 200 makes HIVrelated problems less likely. Check which antiretrovirals the patient is on, and check for side effects in the BNF section 5.3 and on page 74. Conditions that require urgent referral Serious conditions due to HIV disease affect patients with CD4 counts below 200 cells/L (except TB, see page 29). Symptoms that require careful assessment include: respiratory visual (even if apparently minor, such as floaters) progressive or acute neurological problems. For more information see pages 27-31. Side effects of ART are sometimes serious or even life-threatening check which medication the patient is on. Commoner conditions Many HIV-related problems are also common in patients who do not have HIV for example, shingles and seborrhoeic dermatitis. Management of such conditions is generally the same, and the GP is likely to be familiar with treatments. However, the immunosuppressed patient may require longer treatment than other patients. For guidance on management of commoner individual conditions, see Quick reference page 75.
55
SECTION 3
Caring for people on antiretroviral therapy (ART)
ART has had an enormous impact on morbidity and mortality from HIV disease in those countries which have been able to afford the drugs. New drugs and strategies are continually being developed. Your patient (particularly if recently infected) has a good chance of living with their HIV for decades.
How the drugs act Anti-HIV drugs are classified in groups according to where they act in the replication cycle of the virus.
Reverse transcriptase inhibitors These drugs act on the enzyme (reverse transcriptase) that is key to transcribing the viral RNA into proviral DNA. They are divided into: nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs) non-nucleoside reverse transcriptase inhibitors (NNRTIs) There are only two NNRTIs in regular use at the time of writing efavirenz and nevirapine. Protease inhibitors Viral protease is needed as newly formed virus buds from infected cells.
Reverse transcription
DNA
FI RTI
Fusion Integration
NUCLEUS
HIV
Transcription KEY TO DRUGS FI Fusion inhibitors
The drugs act to block steps in viral replication
PI
56
CLINICAL CARE
A decrease in production of protease means release of immature virus particles. Fusion inhibitors These drugs prevent the viral membrane of HIV fusing with the cell membrane.
Resistance HIV readily mutates in the process of replication. This means that resistance to single anti-HIV drugs develops very readily. For this reason these drugs are used together in combinations of three or more. Drug combinations used in ART For initial regimens, the usual combination is of two NRTIs with one NNRTI. The choice of regimen will depend upon the need to minimise side effects and long-term toxicity, while providing an effective combination likely to suppress the virus long-term and be convenient for the patient. Some people may be taking two NRTIs and one or two protease inhibitors (PIs) while other patients may be taking drugs from several classes. Sometimes tablets containing more than one drug are given in order to aid adherence. When to start antiretrovirals HIV specialists will take into account a number of factors when deciding when to start ART, including the CD4 count and risk of disease progression. The choice of drugs will be informed by: knowledge of effectiveness of combination likelihood of resistance developing to chosen drug transmitted drug resistance (the patient was infected by a strain of virus already showing resistance due to past exposure to drugs) drug toxicity pill burden drug-drug interactions. The indications for commencing treatment and the recommended regimens have changed over time. National guidelines are regularly updated. Adherence to ART regimens Resistance of the virus to ART is minimised if combination therapy is maintained at therapeutic levels in the blood stream. Any interference with their action (for example, through drug interactions) or with their administration (for example, through not adhering to prescribed regimens) can lead to resistance developing. Drug resistance, once established, is irreversible. Cross-resistance between classes of drugs means treatment choices are further limited. If people with hypertension miss out their medication for a short period of time, it will still be effective when they re-start. Unfortunately this is not the
57
See British HIV Association (2003) Guidelines for the treatment of HIVinfected adults with antiretroviral therapy, at www.bhiva.org
important!
Adherence is essential to prevent drug resistance developing
SECTION 3
case with antiretroviral therapy. Adherence to a long-term drug regimen is one of the biggest challenges to those who live with HIV as well as to those who support them. The timing of the medication through the day may be complex for example, a patient might be on one drug that Adherence to a long- must be taken some time before meals, but another that term drug regimen is must be taken directly after. Even without these practical complications, it is hard to sustain a regular regimen without one of the biggest losing motivation or even simply forgetting doses. challenges to those Monitoring adherence is something the primary care team can do well. When patients are seen, the GP or who live with HIV as practice nurse should assess and monitor how they are well as to those who coping with taking their medication and whether they are missing doses. Patients need to understand the reasons support them. behind the requirement for optimal adherence as well as the possible consequences of missed doses. If they discontinue or repeatedly miss doses, try to explore the reasons for this. In some areas HIV specialists can arrange adherence support.
Monitoring progress Monitoring of ART is primarily by viral load (see page 16). The aim is to reduce the viral load to <50 copies/ml (current limit to detection) by three to six months. Drug interactions PIs and NNRTIs are the groups most affected by drug interactions, being metabolised via the cytochrome P450 enzyme system in the liver. These interactions can lead to both increased toxicity and decreased efficacy. Dietary substances, herbal remedies and recreational Check for drug interactions on: www.hiv-druginteractions.org drugs can all interact significantly. For further information see: www.hiv-druginteractions.org. Please note that on this site the interaction charts currently list only interactions for PIs and NNRTIs. Interactions for NRTIs with drugs other than the PIs and NNRTIs are not listed. This site includes dietary substances (under herbals/nutraceuticals) and recreational drugs (under illicit/recreational). In some areas advice from specialist pharmacists is available. ART side effects While the benefits of ART are enormous, side effects are common and some are very serious. Even if the patient is not too unwell at presentation, many conditions will progress if ART is continued. However, as antiretrovirals should not be stopped without good reason, management should virtually always be discussed with a specialist before action is taken. An exception to this would be a clinical emergency when advice cannot be obtained. It may take some time for a drug regimen to be found that suits the patient. Because some drugs have significant side effects at first,
HIV IN PRIMARY CARE
58
CLINICAL CARE
treatment centres tend to monitor patients more closely for the first six to eight weeks of therapy. For a full list of both serious and minor side effects, see the BNF section 5.3. See Quick Reference page 74 to identify which group each drug is in. Minor side effects ART can cause a huge range of minor side effects, which are generally listed in the BNF. Be careful that minor symptoms do not herald a major side effect check the major side-effects list below. GPs will often be able to manage minor side effects in the normal way. However, they should always check for drug interactions (see page 58). Symptomatic treatment is given on pages 75-78 (a guide to managing HIV-related problems). Serious or unusual side effects Side effects are considered unusual when they are peculiar to ART. In other words, they are not the type of problem that GPs would normally consider could be due to medication. In addition, some serious unusual side effects of ART can present in an insidious way, leaving the GP at risk of overlooking their significance. Serious or unusual side effects of NRTIs Hypersensitivity Abacavir usually within first six weeks, but not exclusively. Can be lifethreatening. Typically causes fever or rash, but may cause a range of non specific symptoms such as fever, vomiting or myalgia. Seek advice urgently if suspected.
Lactic acidosis and hepatomegaly Probably caused by all NRTIs. This potentially life threatening problem may present with non-specific symptoms such as nausea or loss of appetite. In clear-cut cases patients will be obviously unwell acidotic, with hepatomegaly, deranged liver function and raised serum lactate. They may have abdominal pain. Such patients need hospital admission and all ART medications are usually stopped. However, some patients are relatively well with a slightly raised lactate and simply need closer monitoring by their specialist. These patients may continue on ART.
Bone marrow suppression (anaemia, neutropenia) Most commonly zidovudine, but also lamivudine and stavudine. Pancreatitis Most commonly didanosine, but also stavudine, zalcitabine, abacavir, and lamivudine. Specialists will monitor amylase in patients on these drugs.
HIV IN PRIMARY CARE
59
SECTION 3
Peripheral neuropathy Mainly with didanosine and stavudine, less commonly lamivudine and zalcitabine. (The latter is rarely used.) Management of neuropathic pain generally consists of either tricyclic agents or anti-convulsants such as sodium valproate or gabapentin. Acupuncture can also be very helpful for some patients. Anaesthetic neuropathies are more difficult to manage and significant functional disability sometimes results. Lipoatrophy This is possibly associated with all NRTIs. Stavudine is considered the most implicated, and is currently not recommended as first line therapy. This is subcutaneous fat loss that can be one component of lipodystrophy (explained in more detail below see PIs). It may be associated with hyperlipidaemia and/or diabetes (see PIs below). Serious or unusual side effects of NNRTIs Hypersensitivity Nevirapine Usually within the first four weeks, but not exclusively. Can be lifethreatening. Typically causes rash and Stevens Johnson-type syndrome.
Hepatic toxicity Nevirapine Very rare. May be fatal. Psychiatric problems Efavirenz Nightmares, sleep disturbances, mood changes, behaviour changes. Vivid (life-like) dreams commonly.
important!
Hyperlipidaemia may be associated with lipodystrophy (see page 61), but can also occur in patients on ART who do not have obvious lipodystrophy.
Hyperlipidaemia All PIs (and possibly NRTIs) apart from possibly atazanavir. ART can raise cholesterol and triglyceride levels sometimes to an alarming degree. Diet can control levels in some, but those with high levels are increasingly treated with statins (Atorvastatin, Pravastatin) and fibrates (Bezafibrate). Care must be taken when selecting such drugs due to interactions and hepatic metabolism. It still remains unclear if hyperlipidaemia will lead to a rise in cardiovascular disease. However, it seems wise to pay attention to other traditional CVD risk factors such as hypertension and smoking.
HIV IN PRIMARY CARE
60
CLINICAL CARE
Lipodystrophy. One of the biggest fears of patients taking ART, this syndrome may also be associated with metabolic
MEDICAL ILLUSTRATION UK LTD
Lipodystrophy First described with PIs, but may be associated with most antiretrovirals. At the time of writing, it is unclear to which drugs it can definitely be attributed. Lipodystophy is a syndrome probably caused by ART in which there are changes in the distribution of body fat. In some individuals this is characterised by subcutaneous fat loss causing facial (particularly cheek and temple) thinning and limb and buttock wasting, sometimes known as lipoatrophy. It is particularly associated with NRTIs. Some patients develop central (truncal) adiposity with an increase in intra-abdominal fat, buffalo hump and breast enlargement. This was initially associated with PIs. These two forms of lipodystrophy often co-exist and may also be associated with other metabolic abnormalities such as diabetes (due to insulin resistance) and hyperlipidaemia. Lipodystrophy may be one of the biggest fears of patients taking antiretroviral combinations. It can be stigmatising and distressing, in some cases resulting in low self-esteem and depression. Awareness of the possibility of lipodystrophy may be a reason for some patients avoiding medication, and for some it may significantly affect adherence. Treatment for this syndrome is still largely unsatisfactory. A number of specialist centres offer treatment with polylactic acid, a filling agent for facial wasting. Diabetes (type 2) All PIs Susceptibility to diabetes probably through insulin resistance is associated with PI therapy. This can be managed in the usual way, but monitoring and additional medication may induce adherence fatigue in some patients. This can impact on both HIV and diabetes. Again, it is important to pay attention to other CVD risk factors in such patients. Diabetes may be associated with lipodystrophy (see above), but can also occur in patients on ART who do not have obvious lipodystrophy. Ureteric colic, nephrolithiasis Indinavir
HIV IN PRIMARY CARE
61
SECTION 3
Side effects of fusion inhibitors As the newest class of antiretrovirals, there is limited knowledge of their side effects at the time of writing. Currently they are given subcutaneously and it appears that most side effects relate to injection sites. However, there is some concern about a form of pneumonitis that may be associated with this therapy.
useful info
Frequently given time the patient will agree to be reviewed at the hospital, or agree to be referred to a different specialist centre.
62
CLINICAL CARE
case history
The dangers of being unaware of a patients HIV treatment
taking combination antiretroviral drugs (including ritonavir) as he did not think it Mr M, aged 38, visited his GP with severe relevant. The GP prescribed ergotamine by unilateral headaches suppository. Mr M later Mr M later died from an which had been present died from an acute acute myocardial infarction. for three days. His myocardial infarction. In previous migraine attacks had responded to this example, the action of the ergotamine was simple analgesics, but this time they had little significantly enhanced by the ritonavir effect. He did not inform his GP that he was inhibiting liver metabolism.
Planning care and advance directives Several life-threatening episodes may occur before the final terminal event. So, if not already addressed, planning should begin early on after immunity has started to deteriorate. People with HIV commonly want to be in control of their care and treatment. All should be helped, if necessary, to express their requirements and preferences, which may change depending on the type of illness or stage of the condition. The desire for maximum patient choice in matters of care and treatment is nowhere more important than during episodes of acute, potentially life-threatening illness or when the patient is clearly approaching the terminal phase. Wherever possible, dying patients should be able to have partner, family, friends and people they trust around them, as well as appropriate medical, nursing and social care. A well-planned death can also help those left behind to cope with their loss. In the UK, living wills or Advance statements about medical treatment advance directives were largely developed by and for code of practice, report of the British Medical people with AIDS, though they are now used more Association, April 1995, second edition due in 2004, available at widely. GPs may be asked to look at such www.bma.org.uk/ap.nsf/Content/codeofpractice documents, or contribute to their contents. In such circumstances it is always advisable to seek further
HIV IN PRIMARY CARE
63
SECTION 3
advice and guidance, for example the BMAs ethical guidance. Copies of an advance directive form can be obtained from the Terrence Higgins Trust. (See page 82 for contact details.)
Involvement of other healthcare professionals Although the course of advanced HIV disease may be more up and down than other conditions requiring palliative care, GPs should still be able to draw on their experience. Continuity and communication are extremely important in palliative care, and general practice is well-suited to providing these. The patient should be offered the support and involvement of palliative services and community nursing if appropriate. Some GPs can harness the support of specialist community nurses in HIV care. Hospice care may be needed. Respite care and symptom-control are currently the most important indications for admission. Wills People with deteriorating immunity should be advised to make a will as a matter of priority to avoid distressing disagreements and resentment after death. For example, at the time of writing same-sex relationships have no legal recognition and long-term partners can be excluded from a share in the estate. Legislation has been proposed in the UK to provide full legal recognition for gay partners. Death certification Although a doctor's general ethical duty of confidentiality to the patient continues beyond his or her death, such ethical obligations are generally overridden where there is a statutory duty to disclose. This is made clear by GMC confidentiality guidance which points out that the law requires doctors to complete death certificates honestly and fully. This can be problematic since death certificates are public documents, and surviving partners or family members may fear the consequences if full details are disclosed; or the patient may not have wished their family to know about their HIV infection. Nevertheless, where HIV infection or AIDS is the cause of death, this must be stated, whatever the views of the patient and/or family. Until recently in cases of HIV-related deaths, doctors have stated the obvious cause of death for example, bronchopneumonia but ensured that the box on the back of the certificate is ticked so that further information can be given at a later date. This has been crucial for the accuracy of national and regional statistical information. Increasingly, however, there is demand for very clear and robust mortality data and at the time of writing it is unclear whether or how this will affect HIV reporting on death certificates in the future.
64
SECTION 4
HIV and the practice team
IN THIS SECTION
Sexual health promotion and HIV prevention in the practice Working with those with diverse needs Practice policies and systems 66 66 67
SECTION 4
Growing concerns about the deterioration of sexual health in the UK is leading some practices to consider how they might play a part in promoting sexual health and reducing HIV transmission. For this role, clinical workers in primary care need both factual information and skills in sexual history taking and risk assessment. Practice nurses and GPs have opportunities to: discuss and assess risk of having or acquiring HIV with individual patients promote safer sexual practices and condom use with those who are or may be at risk promote HIV testing when appropriate promote hepatitis B testing and immunisation when appropriate support harm minimisation with injecting drug users. Sexual health promotion interventions may occur during: travel advice consultations new patient checks contraceptive care cervical screening.
Men who have sex with men This term is used to include both men who identify as homosexual (and may call themselves gay) and those who have sexual encounters with other men without considering themselves to be homosexual. Gay men may have a sense of belonging and access to gay-oriented culture. However, other men who have sex with men may see themselves as bisexual or even heterosexual, are sometimes married, and may not be open about their same-sex encounters. African communities Fear and prejudice against HIV is often very high in African communities, with resultant stigma and secrecy. Many people from very high prevalence countries will know of family members or friends who have had, or died from, HIV. HIV may affect both parents as well as their children (infected or not), creating major family needs. HIV information and safer sex advice, presented in a culturally sensitive way, is essential in this group. The GPs knowledge of the local community also helps in providing a focus of care for families affected by HIV and AIDS. Injecting drug users Those who have acquired HIV through injecting drugs (even if they no longer use drugs) may be aware of a double stigma as drug users they are a socially excluded group, and this may be compounded by their HIV status. Those who have not wished, or been unable, to access support may be locked in a cycle of problems as they try to fund and feed their drug use. Dependent drug use may restrict the ability to attend appointments or take medication regularly. In some, HIV may quite For more information see simply not be a priority in the face of the daily problems associated the Substance misuse with drug dependence. management in general GPs involved in appropriate substitute prescribing in primary care practice website, www.smmgp.demon.co.uk will be aware of the benefits of this for the patient, in terms of harm reduction and access to healthcare.
67
SECTION 4
ensure that your practitioners and clinicians are non-judgmental and empathic to different lifestyles. Consider in-house training for the team develop and implement a non-discrimination policy with your practice then display it to your patients develop and implement an appropriate confidentiality statement then display it to your patients.
Systems and record keeping To support HIV testing There are different systems which may be used to support HIV testing in the practice: a pro forma record sheet or computer template can be used to collect data on individual patients having an HIV test. The contents of a pro forma should be discussed and agreed with clinical team members there is a potential that highly confidential information of little value to future care may be unnecessarily recorded. However, if items are excluded for this reason then a check list or aide-memoire may be needed: an aide-memoire (computer or paper-based) may help ensure that all issues are covered. It does not record individual patient information.
For the patient with HIV Some patients infected with HIV will be anxious about how their HIV status is to be recorded in the practice. It is best to raise the subject so this issue can be addressed and the benefits outlined (as well as the risks if the diagnosis is not clearly recorded). Coding HIV infection Computer systems may have different ways or different options for coding HIV infection. Computer screens should not be visible to third parties, although this may be difficult to achieve in a small consulting room. If screens are visible to patients, the visibility of what is recorded should be considered, noting the fact that the patient may be accompanied, but not consulting for an HIV-related problem. The practice will need to be able to search for patients with HIV infection in order, for example, to invite them for flu immunisation or to invite women for annual smears. Records to support clinical care The success of practice systems depends on reliable and rapid communication from the hospital each time the patient has attended and also when significant test results become available. Records of antiretroviral and other drugs Even if drugs are prescribed solely by the hospital, a clear record should be kept. On some practice computer systems it is possible to keep a
68
record of drugs prescribed outside, which is the safest option as long as each and every hospital letter is checked for medication changes. Records of CD4 count and viral load Computer systems may enable a simple template to be set up for use with patients with HIV. The most recent blood results can then be entered when they are made available by the hospital. Review date A review date system can act as a reminder to check that records are up to date. It is better to spend time chasing an absent CD4 result before you are faced with a patient with a bad cough.
Health and safety Hepatitis B immunisation The practice should have a system to ensure that all staff who handle clinical specimens are immune to hepatitis B.
Prevention of needle stick injuries Universal precautions in handling sharp instruments and body fluids are essential to reduce the risk of contracting HIV or other blood-borne viral infections in the healthcare setting. Approved sterilisation procedures and adequate disposal of sharp instruments are crucial components of this important! process. It is easy to forget the number of undiagnosed bloodborne infections, so it is essential to assume that all patients A high risk needle stick are potentially infected.
injury requires rapid and decisive action. Ensure all team members are aware of the practice policy on PEP.
Management of needle stick injuries A high risk needle stick injury requires rapid and decisive action if post exposure prophylaxis (PEP) For PEP is to be given in time. Discuss, develop and see p19 implement a practice policy on PEP and ensure all team members are aware of its existence and whereabouts. PEP policies in primary care should: advise how to manage the wound make clear the urgency and limited window of opportunity make clear who should be contacted for advice in your Further information to support locality and how development of your policy can be found in HIV post-exposure take into account other blood-borne viruses such as prophylaxis: guidance from the UK hepatitis B and C Chief Medical Officers Expert Advisory be adopted only in association with discussion and Group on AIDS (2004), available at training. www.dh.gov.uk, or obtained from local
infection control or occupational health specialists.
The HIV-infected healthcare worker The majority of procedures carried out in the primary care
HIV IN PRIMARY CARE
69
SECTION 4
setting (assuming appropriate infection control procedures) pose no risk of transmission of HIV from healthcare worker to patient. Employing people infected with HIV is generally not a risk except in certain very specific situations where patients tissues might be exposed to a carers blood following injury (exposure prone procedures). However, the Department of Health requires all healthcare workers who are infected with HIV to seek appropriate expert medical and occupational health advice, and this should include (where relevant) how to modify or limit their work practices to avoid exposure prone procedures. HIV-infected healthcare workers must not rely on their own See Department of Health (2002) assessment of the risk they pose to patients. Guidance on the management of While protecting the health and safety of our patients, we infected health care workers and patient notification available at must at the same time respect the right to confidentiality of our www.dh.gov.uk staff and colleagues. Employers should assure infected healthcare workers that their status and rights as employees will be safeguarded so far as is practicable.
70
SECTION 5
Quick reference
IN THIS SECTION
HIV testing aide-memoire HIV testing pro forma Antiretrovirals by group Drug interactions further information A guide to managing HIV-related problems Useful sources for clinicians Useful sources for patients Bibliography 72 73 74 74 75 79 81 83
SECTION 5
Quick reference
Checklists and sources of further information for doctors and patients HIV testing aide-memoire
Does the patient understand: how HIV is transmitted the difference between HIV and AIDS the medical advantage of knowing HIV status that the test is for antibodies, not the virus itself the significance of the three-month window period and the possible need for a repeat test? Discussion of risk risk to date future risk / risk reduction Discussion of implications of positive test Confidentiality Coping with the wait Who knows you are having the test? Who is it safe to tell? Ask the patient not to drink alcohol or take drugs on day of result Other useful questions Is there any written information that should be given to the patient? Is the test best done in primary care? Should there be any associated tests? Are any repeat tests required to cover the window period? Has the patient given clear consent to HIV (or other) tests? Check their contact details Have you arranged an appointment for the result to be given to patient? Does the patient have a supply of appropriate condoms/lubricant?
72
QUICK REFERENCE
Patient _________________________________________________
Reason for test I patient request I investigation of illness I needlestick I insurance I travel I antenatal I doctor concerned I other:___________________________________________________________ If patient request, reason for test: Other issues (eg depression, relationship problems, worries about sexual orientation, drug use) Assessment of risk Risk behaviours: Timing of risk (especially within 3 months): Patients understanding of risks: Understanding I Nature of HIV test
I I I
I I I
I I
I Other_______________________________________________________________________________ Screen for: HEPATITIS A HEPATITIS B I Yes I No I Yes I No I Yes I No I Yes I No HEPATITIS C CHLAMYDIA
Coping, help and support Is this the right time for a test? What would be the worst thing if the result was positive? Who will you tell? Who do you not have to tell? The HIV test In window period Advise to repeat test I Yes I No Appointment for result ___________________________ Will be accompanied? Support whilst awaiting result (GP, family, friend, telephone helpline)
I I
Yes I No Yes I No
Reproduced with the permission of the Royal College of General Practitioners Sex, Drugs and HIV Task Group and the Primary Care Facilitation Team (Blood Borne Viruses), NHS Lothian.
73
SECTION 5
Antiretrovirals by group
This list was correct at the time of writing. Up-to-date lists of agents are available on the following websites: www.bhiva.org, www.bnf.org, and www.hiv-druginteractions.org
enfuvirtide T-20
Trade names These are not often used for single drug tablets. Trade names of combination tablets Tablets containing more than one drug are used more Trade name Contains commonly and are Combivir lamivudine, zidovudine listed opposite. Trade names are all Kaletra lopinavir, ritonavir Trizivir abacavir, lamivudine, zidovudine given in the BNF.
74
QUICK REFERENCE
Constitutional symptoms
Condition Night sweats Fatigue Weight loss Anorexia Notes Exclude serious causes Exclude serious causes Test for low testosterone in men TFTs in all Management Little helps: supportive management only Approach as for palliative care. High calorie supplements. Testosterone replacement sometimes used if deficiency confirmed, seek specialist advice.
Skin conditions
Condition Fungal infections Notes Management Generally respond to topical antifungals. Prolonged or repeated treatment may be required. Will respond to antivirals such as aciclovir but longer courses at higher doses may be needed. Long term use of antivirals is helpful if the problem is recurrent. Cryotherapy.
Warts Molluscum contagiosum Bacterial infections eg impetigo folliculitis Seborrhoeic dermatitis Psoriasis Kaposis sarcoma
Topical antibiotics. Oral antibiotics needed more commonly than in patients with intact immunity. Topical anti-fungal and hydrocortisone combinations. Anti-fungal shampoos may be helpful. Usual management, but may be much less responsive. Will require specialist treatment.
75
SECTION 5
The mouth
Condition Oral candida Notes Can cause significant discomfort and difficulty in eating/drinking Management Topical or systemic anti-fungal agents (nystatin, fluconazole). Long term use of antifungals occasionally indicated if the problem is recurrent. Topical oral steroid creams. Sometimes improved by a course of aciclovir (but oral hairy leukoplakia is usually asymptomatic and does not require treatment). Chlorhexidine mouth washes. Oral metronidazole. Referral to dentist. Requires specialist treatment. May disappear with ART. Oral antibiotics. Referral to dentist.
Aphthous ulceration Oral hairy leukoplakia Gingivitis Maintaining good oral hygiene and dental care is important for all immunocompromised patients
Possible causes: HIV in the intestinal mucosa intestinal pathogens side effect of ART Take stool samples
76
QUICK REFERENCE
Respiratory problems
Condition Chest infection Notes Exclude PCP see pages 27-28 Exclude TB-like infections see page 29 Management Ordinary chest infections will respond to the usual antibiotics such as amoxicillin.
Neurological problems
See also page 30 for serious conditions that require admission Condition Peripheral neuropathy Notes May be caused by HIV or ART Management Pain management similar to usual approaches to neuropathic pain. Gabapentin or other drugs used in neuralgia may help.
Genital problems
Condition Notes Genital candidiasis Management Topical or systemic anti-fungal agents (clotrimazole, fluconazole). Systemic antifungals are sometimes used long term to prevent recurrence. Aciclovir may be needed in longer courses and at a higher end of the dose range than usual. Long-term use of aciclovir or similar may be used to suppress frequent recurrences. Frequently recurrent and more difficult to treat. Topical therapy (podophyllotoxin or imiquimod) or cryotherapy may help. Refer to GUM clinic unless responding well to topical therapy.
Genital herpes
77
SECTION 5
Sexual dysfunction
Condition Erectile dysfunction Loss of libido Notes May be multifactorial. HIV related causes include: effect of HIV fear of transmitting infection ART vascular problems In men check testosterone level Management Sildenafil and tadalafil can be used, but they interact with PIs and NNRTIs and expert advice should be sought. Testosterone replacement is sometimes used on specialist advice.
Psychiatric problems
Condition Stress Depression Bipolar disorder Notes Stress is common May be exacerbated by stigma May be seen more commonly in people with HIV Some antiretrovirals may be associated with psychiatric disturbance Can cause functional impairment and lead to significant care needs Management Supportive counselling and/or specialist or psychological support is sometimes necessary. Beware drug interactions if considering antidepressants.
Visual problems
See page 30 for CMV retinitis, a serious condition that requires urgent referral to ophthalmology.
78
QUICK REFERENCE
79
SECTION 5
Useful reference documents to have in the practice Association of British Insurers & British Medical Association (2002) Medical information and insurance. Joint guidelines from the British Medical Association and the Association of British Insurers. London: British Medical Association. (Available at www.bma.org.uk)
Department of Health (1996) Immunisation against infectious disease. London: HMSO. (The Green Book available at www.dh.gov.uk with new chapters and updates) Carter Y, Weyman A, Moss C and Belfield T (eds). Handbook of sexual health in primary care. London: fpa. For publication in 2005. General Medical Council (2004) Confidentiality: protecting and providing information. London: General Medical Council. (Available at www.gmc-uk.org) Rogstad et al (2004). HIV testing for patients attending general medical services: concise guidelines. Clinical Medicine 4:136-9. UK Health Departments (2004) HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers Expert Advisory Group on AIDS. London: Department of Health. (Available at www.dh.gov.uk)
80
QUICK REFERENCE
Other written resources for people with HIV NAM patient information series (currently 10 booklets) Plain English information on key treatment topics. For organisations 50p each, minimum order 10. Order by phone (020 7840 0050), fax (020 7735 5351) or online (http://aidsmap.com/bookshop/order_form.asp) Available free for people personally affected by HIV (email [email protected]). Electronic versions can be downloaded from the NAM website (http://www.aidsmap.com/publications/infoseries/index.asp)
Terrence Higgins Trust (THT) Living Well leaflet series Information to enable people living with HIV to remain well informed and positive about life. Prices vary according to booklet and quantity ordered. For more information see http://www.tht.org.uk/publications/pubs_liv.htm Positive Nation, the UKs HIV and sexual health magazine, published by the UKC (UK Coalition of People Living with HIV and AIDS). Free to anyone living with HIV. For subscription details see http://www.ukcoalition.org/PositiveNation/subscriptions.html
81
SECTION 5
Organisations for support and information You may well have local organisations working with people with HIV. Here we list just a few national organisations, which may give you the means of identifying local ones.
Terrence Higgins Trust (THT) www.tht.org.uk A large charitable organisation with services in many British towns and cities. Produces a wide range of written resources on HIV prevention and living with HIV and runs the THT Direct helpline (0845 1221 200). For an advance directive form (see pages 63-64) phone the helpline. National AIDS Manual (NAM) www.aidsmap.com Extensive online information on treatments and research. Database of HIV organisations worldwide (including UK). Some online information resources available in French, Portuguese and Spanish. Also publishes comprehensive HIV reference collection, The NAM Manual. National sexual health helpline 0800 567 123 24-hour, free, confidential helpline for anyone concerned about HIV or sexual health. Can provide details of local HIV organisations. Waverley Care www.waverleycare.org Charity providing support services and information in Scotland. (Information centre: 0131 661 0982). THT Cymru www.tht.org.uk/regions/tht_cymru Regional branch of Terrence Higgins Trust, providing support services and information in Wales. (Helpline: 0800 074 3445). The HIV Support Centre www.thehivsupportcentre.org.uk Provides support services and information in Northern Ireland, including a helpline (0800 137 437).
82
QUICK REFERENCE
Bibliography
Adler MW (ed) ABC of AIDS. London: BMJ Publishing Group. Association of British Insurers and British Medical Association (2002) Medical information and insurance. Joint guidelines from the British Medical Association and the Association of British Insurers. London: British Medical Association. (Available at www.bma.org.uk) BHIVA Writing Committee on behalf of the BHIVA Executive Committee (2003) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 4 (suppl 1): 1-41. (Available at www.bhiva.org) British Medical Association and Association of British Insurers (2003) GP insurance package. London: British Medical Association. (Available at www.bma.org.uk) British Medical Association (1995) Advance statements about medical treatment code of practice, report of the British Medical Association. 2nd edition due in 2004. (Available at www.bma.org.uk) British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). (New edition every six months available at www.bnf.org) Carter Y, Weyman A, Moss C and Belfield T (eds). Handbook of sexual health in primary care. London: fpa. For publication in 2005. Department of Health (1996) Immunisation against infectious disease. London: HMSO. (The Green Book available at www.dh.gov.uk with new chapters and updates) Department of Health (2001) Oral sex and transmission of HIV statement of risk (Available at www.dh.gov.uk) Department of Health (2003) Screening for infectious diseases in pregnancy: standards to support the UK antenatal screening programme. London: Department of Health. (Available at www.dh.gov.uk) General Medical Council (2004) Confidentiality: protecting and providing information. London: General Medical Council. (Available at www.gmc-uk.org)
83
SECTION 5
Lyall EG, Blott M & de Ruiter A et al (2001) British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIV Medicine 2: 31434. (Full version available at www.bhiva.org) Medical Foundation for AIDS and Sexual Health (2003) Recommended standards for NHS HIV services. London: Medical Foundation for AIDS & Sexual Health. (Available at www.medfash.org.uk) Rogstad et al (2004). HIV testing for patients attending general medical services: concise guidelines. Clinical Medicine 4:136-9. UK Health Departments (2002) AIDS/HIV infected health care workers: guidance on the management of infected health care workers and patient notification. A consultation paper. (Replaces the 1998 guidance. Available at www.dh.gov.uk) UK Health Departments (2004) HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers Expert Advisory Group on AIDS. London: Department of Health. (Available at www.dh.gov.uk)
84
SECTION 6
Subject index
INDEX
Subject index
Notes: page numbers suffixed by 'f' indicate figures, those suffixed by 't' indicate tables. A abacavir 59, 74 abscess, dental 76 aciclovir 77 acupuncture 60 advance directives 6364 aetiology 11f African communities 51, 67 AIDS 10f, 14 aidsmap 79 amprenavir 74 anaemia 29, 36, 59 anorexia 75 antenatal care 19, 42, 54 antibody test (HIV) see testing (HIV antibody test) antiretroviral therapy (ART) 10, 18, 20, 5662 adverse effects 55, 58-62 CD4 counts 16, 57 combination therapies 57 drug interactions 58, 63, 74 drug names by group 74 drug resistance 18, 57 hypersensitivity 59, 60 impact on death rate 10 initiation and monitoring 54 mode of action 5657 patient adherence 5758 in pregnancy 19 prescription records 68 side effects 55, 5862 viral load 17, 58 see also individual drugs assisted conception 5354 Association of British Insurers (ABI) 40 asylum seekers 51, 54 atazanavir 60, 74
86
B bacterial skin infections 33, 75 bezafibrate 60 bipolar disorder 78 blood/blood products, screening 20 bone marrow suppression 59 bottle feeding 54 breast-feeding 19, 54 British Association for Sexual Health and HIV 79 British HIV Association 79 bupropion 53
C cancer 14, 31, 33, 34 risk and CD4 counts 15t see also specific tumours candidiasis 76 genital 77 oesophageal 35, 76 oral 25, 34, 76 cardiovascular disease prevention 53, 60 CD4 cells antiretroviral therapy indication 16, 55, 57 counts 13, 1516, 15t, 62 primary infection 25 records 69 viral load relationship 16f, 17 drug treatments, sites of action 56 infection 13 opportunistic infection prophylaxis 62
HIV IN PRIMARY CARE
INDEX
pneumocystis pneumonia 27 record keeping 69 cervical cancer 14, 31, 52 cervical screening 52 caesarian section 19 chest infections 28, 29, 77 chlamydia testing 44 cholesterol levels 60 clinical care 5164 ART see antiretroviral therapy (ART) death rates, impact on 10, 10f GP role 5455 health promotion 19, 51, 66 immunisation 20, 5253 non-compliant patients 62 reproductive health and fertility 5354 screening see screening specific patient groups 5051 terminal illness 6364 Combivir 74 community nurses 64 computer systems 6869 condoms 19, 4142, 51, 53 rupture 20 see also contraception confidentiality 23, 6768 death certificates 64 infected healthcare staff 70 insurance reports 40 records 44 contraception 53 oral 53 see also condoms co-trimoxazole 62 cryptococcal meningitis 30 cytomegalovirus (CMV) infection 30
regimens 53 depression 78 dermatitis, seborrhoeic 32, 55, 75 diabetes 53, 61 diagnosis 2247 clinical 2324 communication 23, 36, 42, conditions associated with longstanding HIV infection 2736 see also specific conditions late 23, 37, 39 methods see testing (HIV antibody test) opportunities 2223 primary infection 2426 diarrhoea 25, 35, 52, 76 didanosine 59, 60, 74 differential diagnosis 2324 discrimination 6667, 6768 drug interactions 58, 74 drug names with numbers (eg d4T) 74 drug users 20, 51, 67, 79 dyslipidaemia 53
E efavirenz 56, 60, 74 emtricabine 74 enfuvirtide T-20 74 Epidemiology: Health Protection Agency 79 erectile dysfunction 78 eye problems 30
F fertility 5354 fibrates 60 folliculitis 33, 75 fosamprenavir 74 fungal skin infections 33, 75 fusion inhibitors 18, 57, 62, 74
D death, patient advance directives 6364 death certificates 64 death rates 10, 10f dental abscess 76 dental dams 19 depot medroxyprogesterone acetate
HIV IN PRIMARY CARE
87
INDEX
G gabapentin 60, 77 gastrointestinal conditions 35, 76 see also specific conditions gay men 5051, 67 wills 64 genital problems 25, 35, 37, 77 gingivitis 34, 76 GPs, clinical care role 5455 I immunisation 20, 5253 Immunisation Against Infectious Disease 52 immunosuppression 25, 27, 62 immunotherapy 62 impetigo 33, 75 indinavir 61, 74 infant feeding 54 infection, primary see primary infection infections chest 28, 29, 77 dental 76 eyes 30 frequency 47 immunisation 5253 opportunistic 14, 28-29, 32, 62 sexually transmitted 13, 35, 51, 66 skin 33, 75 see also specific infections influenza immunisation 52 information sources 7282 HIV testing aide-memoire 72 HIV testing pro forma 73 organisations and websites 79 for patients 8182 injecting drug users 20, 51, 67 insurance reports 40 intra-uterine devices (IUCDs) 53
H haematological problems 36 health and safety issues, primary care teams 6970 healthcare workers, HIV status 6970 health promotion 19, 51, 66 helper T cells see CD4 cells hepatitis A 52 immunisation 52 hepatitis B 13, 52, 66, 69 antenatal screening 19 immunisation 44, 52 testing 44, 52 hepatitis C 13, 69 testing 44 hepatomegaly 59 herpes, genital 35, 77 herpes simplex 33, 75 herpes zoster (shingles) 14, 14f, 25, 33, 55, 75 heterosexually acquired infection 10, 11f high-risk groups 4142, 6667 identification 42 HIV lifecycle 56 p24 antigen 15 HIV antibody test see testing (HIV antibody test) homosexuals 5051, 67 hyperlipidaemia 60
K Kaletra 74 Kaposi's sarcoma 14, 33f management 75, 76 oral involvement 34, 35 respiratory involvement 28 skin tumours 31, 33
L lactic acidosis 59 lamivudine 59, 60, 74 libido, loss of 78 lipoatrophy 60, 61 lipodystrophy 18, 60, 61
HIV IN PRIMARY CARE
88
INDEX
living wills 6364 lopinavir 74 lymphadenopathy 25, 31, 32 lymphoma 14, 28, 31, 32
O oesophageal candidiasis 35, 76 openness in consultation 23, 36 opportunistic infections (OIs) 14, 28-29, 32, 62 risk and CD4 counts 15t oral candidiasis (thrush) 25, 34, 76 oral contraceptives 53 oral hairy leukoplakia 34, 76 oral problems 34, 35, 76 oral sex 19
M malaria prophylaxis 52 malignancies 14 see also cancer Medical Foundation for AIDS and Sexual Health (MedFASH) 5 meningitis, cryptococcal 30 molluscum contagiosum 33, 37, 75 monitoring HIV 13 mother-to-child transmission 19, 42, 54 mouth problems 34, 35, 76 mycobacterial disease, atypical 29 Mycobacterium avium intracellulare 29, 62
P p24 antigen assays 15 palliative services 63, 64 pancreatitis 59 patient information/support 6364, 8182 patient records 6869 patient understanding 43 penetrative sex 19 peripheral neuropathy 30, 60, 77 Pneumocystis pneumonia (PCP) 14, 27 diagnosis 28, 38, 47 pneumocystis carinii 14 pneumocystis jiroveci 14 prophylaxis 62 post-exposure prophylaxis (PEP) 20, 69 postnatal care 54 practice teams see primary care teams pravastatin 60 pregnancy 19, 42, 54 prejudice 6667 prevalence of HIV, UK 10, 12, 12f, 66 antiretroviral therapy effects 10 prevention 1920, 66 primary care teams 6670 health and safety issues 6970 reference documents 80 systems and record keeping 6869 primary HIV infection (HIV seroconversion illness) 13, 14, 2426 symptoms 25 protease inhibitors (PIs) 18, 5657, 74 combination therapies 57
89
N National Asylum Support Service (NASS) 54 natural history (HIV) 1314 needle exchange 20 needle stick injuries 20, 69 nelfinavir 74 nephrolithiasis 61 neurological problems 30, 55, 77 neuropathy, peripheral 30, 60, 77 neutropenia 36, 59 nevirapine 56, 60, 74 new diagnoses of HIV by year, UK 10, 10f, 11f non-compliance, patient 62 non-nucleoside reverse transcriptase inhibitors (NNRTIs) 18, 56, 74 combination therapies 57 drug interactions 58, 78 side effects 60 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) 18, 56, 74 lipodystrophy 61 side effects 5960
INDEX
drug interactions 58 side effects 6061 psoriasis 33, 75 psychiatric problems 60, 78 pityriasis versicolor 33 seroconversion illness see primary infection sexual dysfunction 78 sexually transmitted infections (STIs) 13, 35, 51, 66 testing 44 sexual practices 19 unprotected sex 51, 53 shingles (herpes zoster) 14, 25, 33, 55, 75 skin conditions 31, 32, 33, 55, 75 smoking cessation 53 sodium valproate 60 sperm washing 53 statins 60 stavudine 59, 60, 74 StevensJohnson syndrome 60 stigma 6667 stress 78 substance misuse 20, 51, 67 Substance misuse management in general practice, website 79 symptoms 2324 constitutional 32, 75 neurological/visual 30, 55, 77, 78 primary HIV infection 24-25 respiratory 2829, 55, 77 tumours 31, 33 syphilis 19
R rash, primary infection presentation 24 record keeping 6869 referral pathways 40 after positive test 45 urgent 55 refugees 51 reproductive health 5354 respiratory problems 2829, 55, 77 see also specific conditions retinal cytomegalovirus (CMV) infection 30 reverse transcriptase inhibitors 56 see also non-nucleoside reverse transcriptase inhibitors (NNRTIs); nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); individual drugs rifabutin 62 risk factors in discussions 43, 47 ritonavir 52, 63, 74 Royal College of General Practitioners Sex, Drugs and HIV Task Group 79 rubella 19
T tenofovir 74 terminal illness 6364 testing (HIV antibody test) 1517, 4047 aide-memoire 72 antenatal screening 19, 50 at-risk patients 4142 guidelines 29 indications 4142 insurance reports 40 laboratory support 40 negative result implications 45 patient requests 41 positive result implications 43, 4546 pre-test discussions 42, 4345, 47 primary HIV infection 24
HIV IN PRIMARY CARE
S safer sex practices 19, 51, 66 saquinavir 74 screening antenatal 19 blood/blood products 20 cervical 52 HIV antibody test see testing (HIV antibody test) Infectious diseases in pregnancy 19 seborrhoeic dermatitis 32, 33, 55, 75
90
INDEX
pro forma 73 raising the subject 42 results, informing patients 4546 screening for HIV 42 systems and record keeping 6869 thrombocytopaenia 36 thrush (oral) 34, 76 tinea cruris 33 tinea pedis 33 tipranavir 74 toxoplasmosis 62 treatment see clinical care Trizivir 74 tuberculosis (TB) 14, 29, 32, 37 tumours 14, 31, 33, 34 risk and CD4 counts 15t see also specific tumours
U undiagnosed infection (HIV) 12, 13, 40 Unlinked anonymous testing programme 13 unprotected sex see sexual practices ureteric colic 61
V viral load 1617, 16f, 69 antiretroviral monitoring 58 viral skin infections 33, 75 virus (HIV) see HIV visual problems 30, 55
W warts 33, 35, 75, 77 websites, information sources 79 wills, dying patients 64
91
An essential guide to HIV for GPs, practice nurses and other members of the primary healthcare team
ISBN 0-9548615-1-5
ISBN 0-95486151-5
Medical Foundation for AIDS & Sexual Health BMA House, Tavistock Square, London, WC1H 9JP Tel: 020 7383 6345 Fax: 020 7388 2544 Email: [email protected] www.medfash.org.uk
9 780954 861513